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Magnetic Resonance Imaging (MRI) is a leading anatomical imaging modality for disease 
diagnosis. With the aid of Gd3+ based contrast agents, high resolution images of biological structures can 
be obtained. However, there is an increased need for contrast agents that are responsive to specific analytes 
and chemical environments. Paramagnetic Chemical Exchange Saturation Transfer (PARACEST) agents 
that utilize a paramagnetic lanthanide ion chelated with a ligand have shown great promise in this area. 
Lanthanide ions also possess luminescence properties that do not suffer from common limitations of 
conventional optical imaging agents such as autofluorescence and photobleaching. The projects described 
in this thesis aim to capitalize on the dual MRI and optical characteristics of lanthanide ions through the 
synthesis and characterization of a series of bimodal Eu3+ and Tb3+ complexes. Chapter one contains an 
overview of lanthanide complexes, MRI, and optical imaging. Chapter two details a study on the effect of 
quinoline-amide substituent position on the optical properties and stabilities of a library of Eu3+ complexes. 
In chapter three the effect of varying side-chain identities of Tb3+ and Eu3+ complexes is investigated. The 
results obtained from these projects indicate that minor changes in ligand structure can have a significant 
impact on the imaging properties and stabilities of these lanthanide complexes. This insight can be applied 








Chapter 1. An Introduction to Magnetic Resonance Imaging (MRI) and 
Optical Imaging 
 
1.1 Lanthanide Ions 
 
The lanthanides appear in the Periodic Table as the inner transition metals in Period 6 (#57-70).1 They 
are often visually separated from the main body of the periodic table and included with the actinides (Figure 
1-1).1,2 Commonly referred to as the “rare earth elements”, the lanthanides are distinguished from other 
elements by their valence f-orbitals.3 The electrons in the 4f orbitals along with those in the 5d orbitals of 
lanthanides are located closer to the nucleus and are well shielded by the 5s and 5p orbitals.3 Therefore, 4f 
electrons do not participate directly in bonding and, thus, their spectroscopic and magnetic properties are 




Figure 1-1. Lanthanide series on the Periodic Table. The Lanthanides are located in Period 6 (red box).1  
 
  
Lanthanides primarily adopt the +3 oxidation state in compounds and demonstrate unique properties 
that make them useful for a range of different applications; from metal making to development of 
luminescent materials.1,3 Mixtures of early lanthanides have been referred to as “mischmetals” and have 
been used in steelmaking to remove impurities and improve the strength of steel.2 High magnetic materials 







devices in electric cars and wind turbines.2 Other lanthanides have been shown to have luminescent 
properties. For example, europium oxide has been used as a red phosphor in displays and lighting, while 




Figure 1-2. Applications of lanthanides. The luminescent capabilities of some lanthanides have proven 
useful for modern technology such as electronic displays and biomedical imaging.6 
  
The paramagnetic and optical properties of different lanthanides have also proven interesting for 
biomedical imaging applications. This has led to the development of imaging agents for disease detection, 
diagnosis, and treatment.7–9 These paramagnetic and luminescent properties form the basis of this thesis 
project on bimodal imaging agents with MRI and optical imaging capabilities.  
 
 
1.2 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is a noninvasive anatomical imaging technique that utilizes the 
same basic principles as Nuclear Magnetic Resonance (NMR). The properties of NMR were first described 
experimentally in 1946 by Bloch and Purcell and translated clinically by Nottingham and Aberdeen in 
1980.10,11 The difference between these imaging modalities is that in NMR, the measurement of chemical 
shifts produces a spectrum while MRI measures the spatial distribution of the intensity of water proton 










Figure 1-3. Schematic of (a) an NMR spectrometer, (b) an MRI scanner, (c) an NMR spectrum of a 
europium complex, and (d) an MR image of a brain.13–15 
 
 
MRI utilizes certain nuclei that possess a spin property with an induced magnetic moment that 
generates a local magnetic field. The 1H nucleus is the most widely studied due to the prevalence of water 
molecules in the body.16 The process by which these nuclei produce an image can be seen in Figure 1-4. 
When a strong, external magnetic field (B0) is applied, the nuclei are aligned either parallel or perpendicular 
to the external field.  The nuclei then precess around the B0 axis in a similar manner as a gyroscope under 
the influence of Earth’s magnetic field. The velocity of their rotation is referred to as the Larmor frequency. 
In order to acquire an image, a radiofrequency pulse (B1) is applied perpendicularly to B0.  The nuclei 
absorb energy from the pulse, causing a change in the net magnetization of the spins.17,18 The energy emitted 
by the nuclei during this transition induces a voltage that is detected by a wire coil and displayed as a free-









a spectrum (NMR).17,18 The varying shades of black and white that outline different structures in an MR 
image is due to the proportions of water found in different parts of the body.19 
 
 
Figure 1-4. (a) Random orientation of hydrogen nuclei in the absence of a magnetic field. (b) Hydrogen 
nuclei aligned parallel to the applied magnetic field B0 with a net magnetic moment Mz. (c) After 
application of the RF pulse perpendicularly to B0, the net magnetic moment tilts. (d) The nuclei realign 
after the RF pulse stops and release energy to produce the MR signal.18  
 
A high resolution MR image can be generated because 1H nuclei in different tissue environments 
have different relaxation times.16 Relaxation refers to the time it takes for the nuclei’s spin to return to 
equilibrium after an RF pulse is applied. These times depend on the molecular characteristics of the tissue.20 
There are two types of relaxation processes, T1 and T2. These relaxation processes are illustrated in Figure 
1-5. T1 relaxation, also known as longitudinal or spin-lattice relaxation, is a measure of the time it takes for 
the energy introduced by the RF pulse to be transferred back to the surroundings. This causes a recovery of 
the magnetization along the z-axis. T2 relaxation known as transverse or spin-spin relaxation refers to the 
loss of phase coherence in the transverse plane. The spinning nuclei move to random orientations in the 









Figure 1-5. Left: Diagram of T1 relaxation. After the RF pulse, the spin is inverted 180. Upon relaxation, 
the spin orientation returns to its position aligned with the Mz axis. Right: Diagram of T2 relaxation. After 
a 90 RF pulse, the spin is oriented in the xy-plane. As it relaxes, the spins “fan out,” reduces the net 
magnetization in the xy-plane.19 
 
Due to different tissues having unique relaxation times, changes in these times can indicate 
abnormalities in the body. For example, an increase in fat seen in muscle atrophy shortens longitudinal and 
transverse relaxation times while elevated water in muscle edema will lengthen both relaxation times.21 
Multiple pulse sequences are used to detect differences in relaxation times, and the image produced is a 
result of different densities of signals from the water protons.16 
 
MRI has been a leading imaging modality in the diagnosis and study of various diseases including 
prostate cancer, uterine cancer, certain liver cancers, and metastases to the bone and brain that cannot be 
imaged well with other modalities such as computed tomography (CT) (Figure 1-6).22–25 Another benefit of 
MRI is the use of non-ionizing radiation to generate the image, which is less detrimental to patients who 











Figure 1-6. MR images (A, B) and CT images (C, D) of the same brain. Yellow arrows in Figure 6A and 
6B point to small lesions that cannot be seen in Figures 6C and 6D.26 
 
1.3 MRI Contrast Agents 
Although MRI has been shown to produce high quality anatomical images, it can be difficult to 
distinguish finer details in structures such as brain tumors.27 To overcome this limitation, MRI contrast 
agents are often used to increase the contrast between normal and abnormal tissue. It is estimated that 25% 
of all clinical MRI examinations utilize contrast agents especially for imaging the brain and spine.28 There 
are many types of contrast agents and these can be categorized by a variety of factors including magnetic 
properties, chemical composition, method of administration, effect on the MR image, biodistribution, and 
application.29 Most contrast agents can be classified as T1 or T2 agents as they produce contrast by 
shortening the longitudinal or transverse relaxation times of tissue.30 These agents will be further explored 









T1 shortening agents are compounds that shorten the longitudinal relaxation time of tissue. This causes 
an increase in signal intensity of T1-weighted MR images resulting in a brightening of the image to produce 
contrast.31 Typical T1 shortening agents are compounds that utilize paramagnetic ions such as Gd3+ and 
Mn2+, which have 7 and 5 unpaired electrons, respectively.32 Research studies show that the unpaired 
electrons of paramagnetic ions decrease the proton relaxation times.27  
 
To date, the most commonly used contrast agents for clinical applications are gadolinium-based 
contrast agents (GBCAs).18 There are currently eight FDA-approved GBCAs in use clinically (Figure 1-
7).33 Gd3+ is the preferred paramagnetic ion for T1-weighted MRI applications because of its high magnetic 
moment and number of unpaired electrons.34 GBCAs can act as both T1 and T2 agents depending on 
concentration.34 At low concentrations, GBCAs act as T1 shortening agents while T2 shortening occurs at 
higher concentrations.34 GBCAs are therefore preferred as T1 agents because the use of higher 
concentrations of GBCAs can potentially be harmful due to the toxicity of free Gd3+ ions.34 When chelated 
to appropriate organic ligands, the agents pass through the kidneys quickly without the metal ion 
dissociating.34,35 Limiting doses of GBCAs to 0.1 - 0.3 mmol/kg of body weight is of particular importance 
for patients with decreased renal function as higher concentrations increase the possibility of heavy metal 
poisoning over time.35 
 
 








Due to heavy clinical use of GBCAs, their properties are well-studied. Low molecular weight Gd3+ 
complexes can effectively detect and diagnose disrupted blood-brain barriers in central nervous system 
(CNS) diseases such as multiple sclerosis and brain tumors.36 Furthermore, in the diagnosis of soft tissue 
injury, GBCAs can make a proper diagnosis three times as likely than use of MRI without contrast.37 
Overall, GBCAs are especially useful in the identification and enhancement of soft tissue injuries and brain 
lesions.37 A comparison of MR images acquired with and without gadolinium contrast can be found in 





Figure 1-8. T1-weighted images of a patient presenting with paresthesia or numbness in the body. The 
pre-contrast image (left) shows an abnormality, though faint and hard to identify. The post-contrast image 
(right) shows bright enhancement of the lesion and was used to help characterize the abnormality.38  
 
 
 Manganese-based chelates represent another group of paramagnetic compounds studied for their 
MRI applications. Mn2+ ions have been found to accumulate within cells via L-type calcium channels and 
increase intracellular longitudinal relaxation time.39 Similar to gadolinium agents, high concentrations of 
free Mn2+ ions pose cardiotoxicity and neurotoxicity risks.40,41 Manganese-based contrast agents are 
therefore designed to be chelated with a ligand that limits the concentration of free Mn2+ in the body. 
Mangafodipir trisodium (Mn-DPDP), an FDA-approved Mn2+ contrast agent for liver and pancreas 
imaging, is one such compound.42 Upon injection, the metal complex is taken up by the liver, and allows 








MR imaging using manganese-based contrast agents is referred to as manganese-enhanced MRI 
(MEMRI) and has also been explored in animal studies as a potential approach to functional brain 
imaging.44,45 A comparison of images of a liver lesion acquired through CT and MEMRI can be found in 
Figure 1-9. The MEMRI image of the liver shows clearer defined margins of the hepatic lesion compared 




Figure 1-9. CT (left, middle) and MR (right) images of a liver of a 51-year-old male upon injection of the 
FDA-approved Mangafodipir trisodium contrast agent. An enhanced view of a lesion (white arrow) can 




T2 agents represent another class of MRI contrast agents that generate contrast through decreasing 
the transverse relaxation time of water molecules. This shortening of the transverse relaxation causes a 
darkening of the MR image through decreasing signal intensity.31 Though not as commonly used as T1 
weighted MRI, there have been applications of Gd3+ and Dy3+ nanoparticles for acquisition of T2 weighted 
MR images. A comparison of T1- and T2-weighted images are shown in Figure 1-10. Areas that appear 










Figure 1-10. MR images acquired through T1 and T2 imaging of a patient’s brain.47 
One of the most commonly studied groups of T2-shortening contrast agents are superparamagnetic 
iron oxide (SPIO) nanoparticles. These nanoparticles have the general formula Fe23+O3M2+O where M is a 
divalent metal such as iron, manganese, nickel, cobalt, or magnesium.48 SPIO nanoparticles are useful for 
bowel contrast, liver and spleen imaging, and MR angiography.49–51 Negative contrast is beneficial when 
imaging the bowel as it decreases noise and other artifacts.52 Iron oxide nanoparticles can also reduce T2 
signal in healthy lymph nodes and liver tissue while abnormalities are unaffected, thus allowing for better 
discernment of diseased tissue.53–55 
 
As previously mentioned, Gd3+-based contrast agents can act as T1 and T2 shortening agents though 
they are typically preferred for their T1-shortening characteristics as this requires lower concentrations. 
Takaya and coworkers suggested that utilizing transverse relaxation in MR cholangiopancreatography to 
visualize biliary structures in diagnosis of neonatal cholestasis could be an application of GBCAs for T2-
weighted imaging. Bile and water have been shown to have long transverse relaxation times, allowing for 
easier visualization of bile over background signal.56,57 Some researchers have explored combining the 
preferred T1-shortening characteristics of Gd3+ with the significant T2-shortening effects of other lanthanide 




Conventional T1- and T2-shortening agents, while having great benefits in the realm of MRI, have 
some limitations with respect to disease diagnosis and specificity. Typical applications of MR contrast 
agents rely upon the increased uptake of an agent by permeable tumors and less on specific targeting of 







antibodies, metals, or other targets associated with different diseases. While some Gd-based MR contrast 
agents are capable of detecting cancer-related targets such as the HER-2/neu receptor, there is still a need 
for ‘smart’ agents that are responsive to their chemical environment.60 Paramagnetic chemical exchange 
saturation transfer (PARACEST) agents are a class of MRI contrast agents that have shown great promise 
in this area.   
 
1.4 Chemical Exchange Saturation Transfer (CEST) 
 
Chemical Exchange Saturation Transfer (CEST) refers to the generation of contrast through 
chemical exchange of two pools of protons; bulk water surrounding the imaging agent and labile protons 
associated with the agent. For PARACEST agents, the exchangeable protons are typically located on a 
water molecule coordinated to a paramagnetic lanthanide ion chelated by a multidentate ligand. Labile 
protons can also be found on amide and hydroxyl functional groups on the chelating ligand. Examples of 




Figure 1-11. PARACEST agent with different pools of exchangeable protons: bulk water (blue), bound 










Figure 1-12. Difference in NMR signal between CEST signal and relaxation of protons back to 
equilibrium. For CEST, chemical exchange occurs to decrease both bulk water and bound proton signals 
while for the relaxation pathway, NMR signal remains unchanged.61  
 
The CEST mechanism can be understood as two independent equilibria processes that happen 
between the two pools of exchangeable protons (Figure 1-12). A pre-saturation pulse is applied to decrease 
the bulk magnetization of the bound water protons by increasing the number of spins aligned against the 
magnetic field (increased spin population in the higher energy state). Due to chemical exchange, low energy 
and high energy spins exchange between the two proton pools. This results in a saturation of the bulk water 
signal due to a net reduction of the bulk magnetization vector along the z-axis. Upon application of a 90o 
radiofrequency (RF) pulse, the bulk water proton signal intensity is decreased due to chemical exchange 











Figure 1-13. T1 weighted (T1w) and CEST images of the thigh of a healthy mouse after injection of a 
Eu2+- based contrast agent. Upon oxidation to Eu3+, the compound is converted from a T1 agent to a 
PARACEST agent. T1 weighted images were acquired at a) pre‐injection, b) 5 min, c) 12 min, d) 16 min 
and e) the CEST image at 17 min.63 
 
 
Multiple conditions must be met for CEST to occur instead of T1 relaxation. The exchange process 
must occur between two magnetically distinct environments and must be slow on the NMR scale. This 
means that the rate of exchange (kex) must be less than the frequency difference between the two chemical 
environments ().64 For this reason, agents with slow-to-intermediate water proton exchange are usually 
preferred for PARACEST applications. The relaxation times of the two pools of protons must also be long 
relative to the exchange rates. Long relaxation times prevent the protons from relaxing back to equilibrium 
before chemical exchange can occur. The difference between an NMR spectrum acquired through CEST 
versus that of protons that relax back to equilibrium is shown in the top row of Figure 1-12. If the relaxation 
times of the proton pools are short compared to the exchange rates, the protons will relax back to 
equilibrium without exchanging and a signal reduction due to CEST will not be observed. However, if 
relaxation times are long, a decrease of both Pool B (bulk water protons) and Pool A (labile protons) signals 




CEST spectra  
 
  In the study of PARACEST agents, characterization of the chemical exchange in a system is 
achieved through acquisition of a Z-spectrum (or CEST spectrum) which is a plot of bulk water signal 







frequencies.66 A sample Z-spectrum of a Eu3+-DOTA complex can be found in Figure 1-14. The large peak 
at 0 ppm corresponds to the direct saturation of bulk water. The other peak at +50 ppm represents signal 
produced from the chemical exchange of bound water molecules of the complex with bulk water molecules. 
Using this CEST signal, one can determine the percent decrease in intensity of the bulk water signal as a 
function of irradiation frequency.67   
  
Figure 1-14. Sample CEST spectrum of a Eu3+ complex and its corresponding NMR spectrum. The 
spectrum shows the bound water resonance residing 50 ppm away from the bulk water resonance.68 
 
1.5 Lanthanide Complexes as PARACEST Agents 
 
Early studies of lanthanide complexes for MR imaging showed that chemical exchange between  -
OH and -NH groups on Diamagnetic Chemical Exchange Saturation (DIACEST) agents and bulk solvent 
could produce an MR signal.64 However, due to the exchangeable protons residing only 1-5 ppm away from 
the bulk water signal, it was very difficult to selectively saturate these labile protons without directly 
affecting the bulk water signal.64,69 For detection of an optimal CEST signal, chemical shift () must be 
larger than the exchange rate between bound and bulk water protons (kex).67 One study showed that 
paramagnetic Eu3+ DOTA-tetraamide complexes having slow-to-intermediate water exchange kinetics 







These larger chemical shifts associated with PARACEST agents allows for acquisition of CEST signal in 
agents with faster water exchange kinetics and ensures that selective saturation of bound water protons does 
not result in direct saturation of bulk water protons.69,70 Though it is feasible with the larger  of 
PARACEST agents to use fast exchanging systems, production of CEST signal in this case require more 
RF power for saturation, which results in significant tissue heating.71 To avoid this issue, PARACEST 
agents with slow-to-intermediate exchange rates are generally preferred.71 
 
The vast majority of PARACEST agents reported to date produce contrast through the slow-to-
intermediate exchange of bound and bulk water molecules.68 Most of these complexes comprise a 
paramagnetic lanthanide ion chelated with a derivative of the DOTA-tetraamide ligand (Figure 1-11).68 The 
CEST signal arising from bound water exchange in a Eu-DOTA-tetraamide complex is usually detected 
near +50 ppm from bulk water, while that of a Nd-DOTA-tetraamide complex is typically found around -
32 ppm.72,73 For Dy3+ complexes, the chemical shift difference between the bound and bulk water protons 
is as large as -720 ppm.72  
 
The presence of amide protons on the DOTA-tetraamide ligand provides another pool of protons 
that can exchange with bulk water protons. For example, Yb-DOTA-tetraamide complexes possess a higher 
number of amide protons compared to bound water protons, which results in a larger PARACEST signal 
due to the presence of more exchangeable protons.74,75 However, the amide proton CEST signal in these 
complexes is shifted only about 20 ppm from the bulk water signal.76 Dy-DOTAM complexes also generate 
CEST signal from the highly shifted amide proton resonance residing +80 ppm away from the bulk water 
resonance.68  
 
Incorporation of hydroxyl and hydroxyethyl side-chains into the DOTA structure is another 
approach in the design of PARACEST agents. Although this method increases the number of exchangeable 
protons available for CEST, the weak ligand field due to the hydroxyl groups leads to small  and lowers 
the magnitude of  the CEST signal.61 
 
1.6 Responsive PARACEST Agents 
 
The design of PARACEST agents that are responsive to a variety of analytes and chemical 
environments has been of particular interest in the biomedical imaging field. The response of these agents 
is typically measured through alterations of exchange rates, ligand structure, and chemical shifts, in the 
presence of the analyte of interest.68,77–79 Phenyl boronate groups incorporated into the ligand structure of a 







acid groups on the Eu3+ complex form a bridge to capture glucose by forming a cyclic ester bond with the 
cis-diol group in glucose. The captured glucose molecule slows the rate of bound and bulk water exchange 
and can be imaged via MRI. As the concentration of glucose in solution increased, the CEST signal also 
increased.  
 
Figure 1-15. Left: ligand with two phenyl boronate substituents. Right: CEST images of phantoms with 
10 mM Eu3+ complex and increasing concentrations of glucose from 5 mM to 20 mM. As concentration 
of glucose increases, CEST signal also increases.78 
 
 
Likewise, the addition of a p-NO2-phenyl substituent to a Eu3+-DOTA-tetraamide complex 
furnished this PARACEST agent with redox sensitivity.77 Upon reduction to p-NH2-phenyl, the CEST 
image darkened (Figure 1-16). The electron-donating p-NH2-phenyl substituent pushes electron density 
from the coordinated amide to the Eu3+ ion, weakening the metal-water interaction and increasing the water 
exchange rate. By monitoring the CEST signal, one can track the reduction of NO2 to NH2, thus 









Another strategy employed in the design of responsive agents is to incorporate a substituent that 
causes a change in the chemical shift of bound water upon interacting with the analyte of interest or when 







with a ketone-phenol group induced pH sensitivity in this complex (Figure 1-17). As the pH of the solution 
increased from pH 6.0 to 7.6, deprotonation of the phenolic proton occurred and resulted in a gradual change 
in chemical shift of the water exchange peak from +50 to +54 ppm.79  
 
 
Figure 1-17. Left: Eu-DOTA-Gly complex with a ketone-phenol group. Right: CEST spectra of the Eu-
DOTA-Gly complex recorded at 9.4 T and 298 K. The insert depicts an expanded view of the water 
exchange peak as a function of pH.79 
   
PARACEST agents have the potential to detect metabolites through binding of the analyte of 
interest to the inner coordination sphere of the lanthanide ion. A Yb3+ complex with a heptadentate ligand 
and six exchangeable amide protons (MBDO3AM) was developed to detect the presence of lactate which 
is associated with the formation of metastases. 80,81 The lactate molecule binds to the inner coordination 
sphere of the Ln3+ ion and causes a change in the amide chemical shift from -28.5 ppm to -20 ppm that is 
proportional to the concentration of the species of interest.80 This change in the chemical shift allows for 
the quantitative measurement of lactate.80 The ligand used in this study and the CEST signal following 









Figure 1-18. Left: The MBDO3AM ligand. Right: CEST spectra of a 30 mM solution of Yb3+-
MBDO3AM complex free (□) and fully bound to l-lactate (▪). Upon binding to lactate the amide chemical 
shift of the Yb3+-MBDO3AM complex changes from -28.5 ppm to -20 ppm.80 
 
 
PARACEST agents have the potential to detect several metal ions in solution by several 
mechanisms. For example, a [Eu(dotampy)] complex containing N,N-bis(2-pyridyl-
methyl)ethylenediamine groups was capable of detecting zinc ions (Figure 1-19) via equilibrium binding 
to the pyridyl groups on this complex.82 The CEST signal around 50 ppm decreased and this signal change 
was attributed to the presence of a coordinated hydroxyl group at this pH on the bound Zn2+ ion that 
accelerated water proton exchange, and led to broadening of the water exchange signal at 50 ppm.  
 
Similarly, Angelovski and coworkers designed a Yb3+-based PARACEST agent with four 
iminodiacetate side-chains capable of binding metal ions like Ca2+.83 This study showed a similar 
phenomenon whereby the CEST effect was altered upon binding to Ca2+ due to a deceleration of the amide 










Figure 1-19. Left: Eu(dotampy) complex binding to Zn2+. A coordinated water molecule on Zn2+ is 
deprotonated at physiological pH to a hydroxyl group. Right: Upon Zn2+ binding to the Eu(dotampy) 




Figure 1-20. Left: Yb3+ and Eu3+ complex designed to bind to Ca2+. Right: CEST spectra of a twenty 
millimolar aqueous solution of YbL1 in the absence (▴) and in the presence of 5 (■) and 100 equiv (♦) of 









Changes in redox properties of tissue can be indicative of diseases like cancer or conditions such 
as hypoxia. The need to detect these types of conditions has inspired the design of redox-responsive 
PARACEST agents. These agents typically produce altered PARACEST signals due to redox-induced 
changes in the oxidation state of either the metal center or the ligand. One such compound that has been 
studied is a Eu2+ complex with glycinate side-chains (Figure 1-21).63 The Eu2+ complex acts as a T1 agent 
because it is isoelectronic with Gd3+. Upon oxidation to Eu3+, the complex produces a CEST effect that 
detects oxidative environments. The complex could not be used to quantify the amount of oxidant present, 




Figure 1-21. T1 weighted and CEST image of the thigh muscle of a healthy mouse post-injection of a 
Eu2+-Gly complex. After 17 min, the complex was oxidized from Eu2+ to Eu3+ and a CEST image was 
acquired.63 
 
A significant advantage of responsive PARACEST agents is the concentration-independent 
approach to signal acquisition which negates the need to know the exact concentration of contrast agent in 
a region of interest.84 The use of concentration-independent methods for monitoring responsiveness can be 
accomplished by the injection of two agents, one responsive and one unresponsive. Aime et al. have used 
this approach to monitor pH changes with the aid of two lanthanide complexes of the same ligand, Yb-
DOTAM-Gly and Eu-DOTAM-Gly.85 The Yb(III) agent, with amide protons shifted 16 ppm upfield, 
responded differently to pH compared to the Eu(III) complex which produced a CEST effect through the 
bound water protons shifted 40 ppm downfield from the chemical shift of the bulk water.85 They found that 
the ratios of the CEST signals from these two complexes could be used to determine pH without knowing 










Figure 1-22. Left: Structure of the DOTAM-Gly ligand. Eu- and Yb-DOTAM-Gly complexes were 
synthesized. Right: Plot of the pH dependence resulting from the ratiometric method following irradiation 
of 10 mM Eu-DOTAM-Gly and 12.5 mM Yb-DOTAM-Gly. The CEST effect was due to the pH 
dependence of the amide proton exchange for the Yb3+ complex while the water proton exchange signal 
from the Eu3+ showed no pH dependence.85 
 
 
Another concentration-independent approach involves the injection of one agent with two chemical 
exchange sites, one of which is responsive, and the other unresponsive to the analyte of interest. Sheth and 
coworkers demonstrated the effectiveness of this method by using a single Yb-DO3A-oAA complex with 
exchangeable amide and amine sites to monitor pH.86 The ratio of CEST signal for both exchangeable 




Figure 1-23. Dependence of CEST on pH using a Yb-DO3A-oAA complex (top). (A) % CEST signal as 
a function of pH of the amide site, (B) % CEST signal as a function of pH of the amine site, (C) The log10 
of the ratio of CEST signal of the amide and amine sites as a function of pH. The log10 of the ratio of 







In vitro studies of PARACEST agents have demonstrated the promise of applying PARACEST 
agents in vivo. The possibility of turning the PARACEST MR signal “on” and “off” with a selective 
radiofrequency pulse eliminates the need to acquire a full pre-contrast MRI image prior to the 
administration of the contrast agent.18 This could potentially shorten the MR scan and alleviate some anxiety 
for the patient. Additionally, PARACEST agents have the potential to not only provide anatomical 
information, but also provide physiological information in vivo. This particular feature could significantly 
improve the efficacy of disease diagnosis and treatment. 
 
1.7 Photophysical Properties of Lanthanide (III) ions 
Lanthanide ions emit light after excitation that spans the UV-NIR regions of the electromagnetic 
spectrum (Figure 1-24).87 This broad span of emission wavelengths allows the development of probes with 




Figure 1-24. Emission spectra of different lanthanide ions.89  
 
 
The excited Eu3+ and Tb3+ metal ions, which emit light in the red and green visible region 
respectively, have narrow emission peaks, making their signal easier to separate from that of conventional 
fluorophores.87,91,92 Most lanthanide ions also possess long-lived luminescence lifetimes of 0.1 - 1 ms, which 
is ideal for time-gated applications.93,94 This enables selective acquisition of luminescence signal after 
background autofluorescence has dissipated.94 A general depiction of selective signal acquisition through 










Figure 1-25. General diagram of time resolved luminescence measurements. Lanthanides have long-lived 
luminescence lifetimes that allow for signal measurement when background autofluorescence has 
dissipated.94 
 
1.8 Lanthanide-based Bimodal Imaging Agents 
 
Given that lanthanide complexes exhibit both MRI and optical imaging capabilities, there exists an 
opportunity to develop lanthanide-based bimodal imaging agents that incorporate both of these imaging 
capabilities. A typical disadvantage to MRI is its low sensitivity, while optical imaging is known to be 
highly sensitive.18 The combination of these two imaging modalities with complementary levels of 
sensitivity provides an opportunity to acquire physiological information at the macro- and molecular scale.18 
For example, a lanthanide complex with both MR and optical imaging capabilities could be employed in 
the context of image-guided tumor resection wherein a preoperative MRI scan is used to localize the bulk 
of a tumor while intraoperative use of optical imaging would help a surgeon delineate tumor margins during 
resection. Such a probe would help facilitate complete removal of cancerous tissue while minimizing 
excessive removal of healthy tissue.  
 
Several approaches to developing bimodal imaging probes with MRI and optical imaging properties 
have been proposed. In one study, the organic dye indocyanine green (ICG) was administered to patients 
after a gadolinium MR contrast agent.95 The results indicated that both imaging modalities were capable of 
differentiating between healthy and malignant breast tissue. It was also suggested that monitoring ICG 







Though the two compounds used in this study have known properties and proven stability in the body, their 
biodistributions may be different.35,96 This would make image co-registration difficult and complicate data 
interpretation. 
 
To combat the problem with differences in biodistribution between an MRI contrast agent and 
fluorescent organic dye, complexes with Gd3+ that incorporate a fluorescent organic chromophore into the 
ligand structure have been proposed.97–99 Gd-DOTA functionalized with 4,4,difluoro-4-bora-3a,4a-diaza-
8-indacene (BODIPY) as well as Gd3+ complexes tagged with fluorescein have shown success in imaging 
cells (Figure 1-26).98,99 Although the issue with biodistribution could potentially be overcome by using 




Figure 1-26. Left: Gd-DOTA-BODIPY derivative. Right: Gd3+ complex tagged with fluorescein.98,99 
 
Another potential approach to the development of bimodal imaging probes involves designing 
nanosystems that incorporate both MRI and optical imaging agents. In one such example, the possibility of 
using Mn3[Co(CN)6]2 nanocubes for T1- and T2-weighted MRI and two-photon fluorescence was 
demonstrated.101 The nanocubes provided high fluorescence signal in the visible region and showed 
potential for long-term cell imaging with reduced photodamage compared to typical UV imaging. The MRI 
capabilities of the Mn2+ nanosystems were also more optimal than previously studied MnO compounds. 
Larson et al. demonstrated similar capabilities with gold-coated iron oxide hybrid nanoparticles.102 The iron 







molecular specific contrast agents for optical imaging.102 Though these nanoparticle-based systems showed 
promise as bimodal imaging agents, the potential risk of nanoparticle toxicity cannot be ignored.103 
 
Lastly, the use of isostructural lanthanide complexes was proposed as a possible way to combine optical 
and MR imaging capabilities. This approach typically involves two lanthanide ions, typically Gd3+ and 
another luminescent lanthanide, chelated by the same ligand. The Gd3+ complex can be used for MR 
imaging while the other lanthanide complex can be used for optical imaging. Allen and Meade designed 
Gd3+- and Eu3+-DOTA complexes that were capable of permeating the cell membrane.104 These isostructural 
complexes were designed with the aim of providing more information about cell environments and 
facilitating transport of different species across cell membranes. Through T1 analysis, the Gd3+ complexes 
were shown to permeate cells and provide images of them through MRI, while two-photon laser microscopy 
was used to detect Eu3+ complex uptake into the cells. With both MR and optical imaging, the complexes 
demonstrated their potential to monitor cell processes such as cell division over time.  
 
Similarly, Crich and coworkers studied Gd3+- and Eu3+-HPDO3A complexes that could be internalized 
by endothelial progenitor cells (Figure 1-27).105 Endothelial progenitor cells (EPCs) are commonly used in 
the engineering of implantable devices such as valves. The two complexes were internalized in the EPCs 
equally without affecting the biological activity of the cells and were visualized through both MR and 
optical imaging. The ability to be internalized and imaged with both modalities shows the possibility for 
these contrast agents to be used to monitor the transplanted cells in vivo, which could possibly replace 
conventional radioactive labeling techniques.105 While the isostructural lanthanide complexes may have 
similar biodistribution, using two complexes may create signal issues in one modality if one complex 




Figure 1-27. Optical and MR images using Gd3+ and Eu3+ chelates to visualize endothelial progenitor 
cells (EPCs). (a) Intracellular uptake of Eu-HPDO3A after 16 hr of incubation. (b) Cells showing 











1.9 Research Goals 
 
The overall goal of the projects to be described was to develop Ln3+ complexes with PARACEST MRI 
and optical imaging properties. The complexes in these projects were designed to be single molecules with 
MRI and optical properties arising from the same lanthanide ion. This approach takes advantage of the 
luminescent capabilities of lanthanide ions such as Eu3+ and Tb3+ that have narrow emission lines and long 
luminescent lifetimes for time-gated applications. Through the use of just one molecule for MR and optical 
imaging, biodistribution issues can be overcome which would render image co-registration and 
interpretation easier. We sought to determine how various structural factors influence the MRI and optical 
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Chapter 2. Impact of Quinoline-amide Substituent Position on the Optical 





Lanthanide ions such as Eu(III) are known to exhibit long luminescence lifetimes, allowing for 
time-resolved luminescence acquisition; however, the use of high energy lasers to directly excite these ions 
could potentially be damaging to biological tissue. To address this issue, organic chromophores can be used 
to absorb the incident light and transfer it to a nearby lanthanide ion. This intramolecular energy transfer 
results in the indirect sensitization of the lanthanide ion luminescence. The goal of this project was to 
investigate the effect of positional differences of quinoline amide substituents on the optical and MRI 
properties of a library of Eu(III) complexes. Each complex comprised a Eu(III) ion chelated by an 
octadentate ligand with an appended quinoline antenna. Indirect sensitization of the Eu(III) luminescence 
by the quinoline pendant arm was observed for all complexes in the library, the magnitude of which was 
found to be dependent on the position of the amide substituent. Quantum yield values were also found to 
be affected by amide substituent position on the quinoline antenna. Triplet excited state energies of the 
chromophore were determined through phosphorescence emission measurements, and the energy 
difference between the triplet excited state of the ligand and emitting state of the lanthanide was used to 
evaluate the efficiency of sensitization by the quinoline antenna. Using luminescence lifetime 
measurements, the majority of complexes were found to possess one bound water molecule, which is 
necessary for MR agents to produce a contrast signal. Kinetic stabilities of the complexes were also 
investigated in order to identify the most inert complexes. Overall, direct coordination of the quinoline 
antenna to the Eu(III) ion resulted in the highest emission intensities and quantum yields, but significantly 











Photophysical properties of Lanthanide ions 
Lanthanide ions such as Eu3+ and Tb3+, which emit light in the red and green visible region respectively, 
have photoluminescence properties that are ideal for optical imaging. These properties, which include long 
luminescent lifetimes and narrow emission peaks, enable the acquisition of luminescence signal after 
autofluorescence has dissipated.1 Each lanthanide ion has different emission profiles allowing for the design 
of luminescent agents that span the entirety of the visible region of the electromagnetic spectrum. The 
emission profiles of Tb3+ and Eu3+ can be found in Figure 2-1, spanning 475 nm – 725 nm.  
 
 
Figure 2-1. Emission spectra of a Tb3+ complex (green) and Eu3+ complex (red). 
 
 
Though the emission properties of lanthanide ions show great promise to overcome the limitations 
of traditional organic fluorescent dyes, free lanthanide ions do not display adequate luminescent capabilities 
when excited directly due to their Laporte forbidden 4f-4f transitions.2,3 Due to this limitation, high energy 
laser sources are generally required to adequately populate the excited states of the Ln(III) ions via direct 
excitation, and these have the potential to damage biological tissue.3,4 
The Antenna Effect 
To circumvent the need for high energy excitation sources, an organic chromophore with a much 
higher molar absorptivity coefficient ( = 104-105 M-1cm-1) can be used to sensitize the lanthanide ion’s 
luminescence.3,5 The process of energy transfer from the antenna to the lanthanide is illustrated in Figure 























2-2. In the initial step, the chromophore is excited with a lower energy light source to promote electrons 
from the singlet ground to the singlet excited state of the antenna. Through intersystem crossing, the triplet 
excited state of the antenna is populated from its singlet excited state. If proper conditions between the 
triplet excited state of the antenna and the emitting level of the lanthanide ion are met, some of the energy 
is then transferred to the excited state of the lanthanide ion. Upon relaxation, light is emitted that is 
characteristic of the lanthanide ion.5–8  
 
Figure 2-2. A) The antenna effect. Upon excitation of the coordinated antenna, energy is transferred from 
the triplet excited state of the ligand to the emitting level of the Ln(III) ion. This causes emission of light 
characteristic of the lanthanide ion’s luminescence. B) 4f-4f transitions of europium and terbium 
complexes and their characteristic emission wavelengths.9 
 
 
 There are a variety of factors that influence the efficiency of energy transfer from the antenna to 
the lanthanide ion.10 One of these factors is the distance between the chromophore and the lanthanide center. 
Pendant antenna have been shown to sensitize a lanthanide ion’s luminescence through the Förster 
resonance energy transfer mechanism and the Dexter mechanism with efficiencies of 1/r6  and 1/er, 
respectively, where r is the distance between the antenna and the lanthanide ion.10 The sensitization 
efficiency of the antenna can be increased by either decreasing the linker length between the antenna and 
the chelating ligand, or by using antennae that directly coordinate to the metal center.11 The ability for 
directly coordinated antenna to undergo energy transfer via both the Förster and Dexter mechanisms usually 








Another factor that can affect the sensitization efficiency of the antenna is the energy difference 
between the triplet state of the ligand and the excited states of the lanthanide ion.5 To prevent back energy 
transfer from the lanthanide to the ligand, the energy difference between the triplet excited state of the 
ligand and the emissive levels of the lanthanide should be at least 1850 cm-1.13 A smaller energy gap 
between the triplet excited state of the ligand and the emissive levels of the lanthanide favors relaxation 
through non-radiative pathways, such as back energy transfer from the lanthanide ion to the ligand, over 
emission of light through the emissive levels of the lanthanide center.13 This energy gap between the triplet 
excited state of the ligand and emissive levels of the lanthanide should also be less than 7000 cm-1 to allow 
for energy transfer to occur.14 The electron transfer to the lanthanide ion must also be favored over 
competing phosphorescence and non-radiative energy dissipation pathways.9  
 
Lastly, the number of bound water molecules can influence the sensitization of the lanthanide ion’s 
luminescence by the appended antenna. The ligand can affect the coordination environment of the 
lanthanide complex, which can influence the number of water molecules that can bind to the lanthanide 
ion.10 Solvent H2O molecules have the ability to quench luminescence intensity through energy loss from 
highly oscillating X-H groups (X = C, N, O).15 Ligands that occupy all Ln3+ coordination sites prevent water 
from coordinating to the metal ion and increase the quantum yield of the lanthanide complex by decreasing 
the number of directly coordinated quenching groups.10,16  
Quinolines as Efficient Antennas for Eu3+  
Aromatic organic compounds such as quinolines are ideal chromophores for the sensitization of 
the luminescence of several lanthanide ions.17 The excitation wavelengths of quinolines (ex > 340 nm) are 
more suited for studying biological systems as lower energy light sources can be used for excitation without 
harming tissue.18 Quinoline derivatives display efficient intramolecular energy transfer from the lowest 
triplet state to the Eu3+ ion, and efficiently sensitize other lanthanide ions such as, Nd3+, Yb3+ and Er3+.18 
This sensitization versatility, has made quinolines a very attractive class of antennae.   
 
 








Complexes with different quinoline-based antenna have been studied. Rizzo et al. have designed 
highly stable and luminescent Eu3+ complexes using a 8-hydroxyquinoline group (Figure 2-3).19,20 They 
found that the 8-hydroxyquinoline antenna was an efficient sensitizer of the lanthanide ion’s luminescence 
and that the complexes were stable in a variety of solvents.19,20 In another study, 3-aminoquinoline (Figure 
2-3) was shown to act as an effective sensitizer of Eu3+ and Tb3+ coordinated with DTPA-bis-amide 
aminoquinoline ligands.21 These complexes displayed enhanced luminescence upon binding to circulating 
tumor DNA in cancer cell lines and showed potential as responsive optical imaging agents.21 In a different 
study, indirectly coordinated 8-aminoquinoline derivatives were shown to greatly sensitize Eu3+ emission.22 
An enhancement of the luminescence of Eu3+ by a factor of 1380 was observed relative to a Eu3+ complex 
without the 8-aminoquinoline antenna, and the ligand was shown to shield the metal center from quenching 
by surrounding water molecules.22 Though there has been much work with Eu3+ luminescence sensitization 
by quinoline antennae, there are no reports investigating the effect of the position of the amide substituents 
in these quinoline systems on the sensitization efficiency of lanthanide complexes.  
Project Goal 
The main objective of this project was to study the effect of varying the amide position of 
aminoquinoline antenna on the photophysical properties of bimodal lanthanide complexes. To this end, a 
library of Eu3+ DOTA-tetraamides with an appended aminoquinoline antenna and three acetamide side-
arms was synthesized (Chart 2-1). A Eu3+ complex with a directly coordinated quinoline chromophore was 
used as a control to investigate the impact of direct versus indirect coordination of the antenna. All ligands 
in this study were designed to be octadentate to allow for binding of one water molecule to the metal center, 
which is important for MRI agents as exchange of these bound water molecules is a potential source of 
MRI contrast.23 With the presence of one water molecule, these complexes have the potential to act as both 
optical imaging and MR imaging probes. The central hypothesis of this project was that changing the 
position of the amide substituent on the quinoline antenna would alter the electronic properties of the 
complexes and ultimately affect the photophysical properties for each complex. The ultimate goal of this 
project was to identify the optimal location of the amide on the quinoline that would maximize 

























2.2 Experimental Methods 
 
Materials and Instrumentation 
 All reagents and solvents were purchased from commercial sources and used as received. Distilled 
water was used in all reactions. Flash Chromatography was carried out using a Buchi Reveleris X2 system. 
1H and 13C NMR spectra were recorded on a Varian 500 MHz NMR spectrometer. Inductively Coupled 
Plasma was performed using a Perkin Elmer 5300 DV optical emission ICP. High performance liquid 
chromatography (HPLC) was performed using an Agilent 1100 Series HPLC. UV-Vis absorption spectra 
were acquired using a Cary 5000 UV-Vis-NIR spectrophotometer. Luminescence studies were performed 
using a Jobin-Yvon Horiba Fluoromax spectrometer. 
 
 




Scheme 2-1. Synthesis of Eu-MP30 
 
 
2‐[(1,4,7,10‐tetraazacyclododecan‐1‐yl)methyl]quinoline. (MP27): Cyclen (2.000 g, 1.16 
mmol) and 2‐(chloromethyl)quinoline (0.622 g, 2.90 mmol) were dissolved in CHCl3 (50 mL). K2CO3 
(0.883 g, 6.38 mmol) was added before being stirred to reflux overnight. The reaction mixture was washed 
with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer was recovered, and 
the pH adjusted to pH 8. That layer was then extracted with CHCl3 (3 × 25 mL). The pH was further adjusted 
to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was dried with Na2SO4, filtered, and the 
solvent removed under reduced pressure to give a yellow/brown oil (0.892 g, 96%). 1H NMR (CDCl3, 500 







(t, 4H, J = 5 MHz, NCH2CH2N), 3.92 (s, 2H, NCH2-quin), 7.45-7.49 (td, 1H, J = 5 MHz, quin-H3), 7.58-
7.60 (d, 1H, J = 10 MHz, quin-H6), 7.63-7.67 (td, 1H, J = 10 MHz, quin-H7), 7.74-7.76. (d, 1H, J = 10 
MHz, quin-H8), 8.00-8.02 (d, 1H, J = 5 MHz, quin-H5), 8.11-8.13 (d, 1H, J = 10 MHz, quin-H4).  13C 
NMR (CDCl3, 125 MHz): δ 45.13, 46.14, 46.32, 47.11, 51.91, 62.01, 120.87, 126.06, 127.46, 127.58, 
128.88, 129.32, 136.67, 147.51, 160.27 
 
2‐[4,7‐bis(carbamoylmethyl)‐10‐[(quinolin‐2‐yl)methyl]‐1,4,7,10 tetraazacyclododecan‐1‐
yl]acetamide (MP30): 2-bromoacetamide (0.516 g, 3.73 mmol), triethylamine (0.680 mL, 4.81 mmol) was 
added to a solution of MP27 (0.377 g, 1.20 mmol) in acetonitrile (25 mL). The mixture was stirred to reflux 
overnight. A white solid was formed, and the reaction mixture was vacuum filtered. The resulting white 
solid (0.449 g, 77%) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 
2.28-2.43 (m, 16H, NCH2CH2N), 2.71 (s, 4H, NCH2C=O), 2.87-2.91 (m, 2H, NCH2C=O), 3.34 (s, 2H, 
NCH2-quin), 7.12-7.14 (d, 1H, J = 10 MHz, quin-H3), 7.35-7.38 (m, 1H, quin-H6), 7.33-7.56 (m, 1H, quin-
H7), 7.64-7.66 (d, 1H, J = 10 MHz, quin-H8), 7.73-7.75 (d, 1H, J = 10 MHz, quin-H5), 7.96-7.98 (d, 1H, 
J = 10 MHz, quin-H4). 13C NMR (D2O, 125 MHz): δ. 51.90, 52.27, 52.50, 56.97, 57.02, 57.15, 61.09, 
121.67, 126.85, 126.99, 127.11, 127.98, 130.35, 137.64,  146.11, 158.66, 177.12, 177.29. LRMS (ESI-
MS): m/z calcd. for C25H37N8O3+, [M+H]+, 485.3, found 485.4; calcd. for C25H38N8O32+ [M+2H]2+, 243.2, 












N‐(quinolin‐2‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (M24). Cyclen (1.001 g, 
5.80 mmol) and 2‐chloro‐N‐(quinolin‐2‐yl)acetamide (0.322 g, 1.45 mmol) were dissolved in CHCl3 (25 
mL). K2CO3 (0.242 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction 
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer 
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH 
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was dried with Na2SO4, 
filtered, and the solvent removed under reduced pressure to give a brown solid (0.357 g, 67%). 1H NMR 
(500 MHz, CDCl3):  2.66 (s, 2H, CH2NCH2), 2.70-2.72 (t, 4H, J = 5 MHz, CH2NH), 2.75-2.76 (m br, 4H, 
CH2NH), 2.77 (s br, 2H, CH2NCH2), 3.00-3.01 (m br, 4H, NHCH2C-quin), 3.37 (s, 2H, CH2C=O), 7.37-
7.39 (td, 1H, J = 5 MHz, quin-H6), 7.58-7.62 (td, 1H, J = 5 MHz, quin-H7), 7.70-7.72 (d, 1H, J = 5 MHz, 
quin-H8), 7.92-7.93 (d, 1H, J = 5 MHz, quin-H3), 8.09-8.11 (d, 1H, J = 10 MHz, quin-H5), 8.41-8.43 (d, 
1H, J = 10 MHz, quin-H4). 13C NMR (125 MHz, CDCl3):  46.10, 46.96, 47.47, 48.72, 53.22, 60.54, 
114.19, 124.91, 126.91, 127.29, 127.79, 129.79, 138.99, 146.99, 151.03, 171.85. 
 
N‐(quinolin‐2‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP42). 2-bromoacetamide (0.393 g, 2.85 mmol), triethylamine (0.520 mL, 3.67 mmol) was 
added to a solution of MP24 (0.327 g, 0.918 mmol) in acetonitrile (25 mL). The mixture was stirred to 
reflux overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting white 
solid (0.170 g, 35 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 
2.89-3.48 (m, 18H, NCH2CH2NCH2C=O), 3.84 (s, 2H, NCH2C-quin), 4.06-4.15 (q, 4H, J = 10 MHz, 
NCH2C=O), 7.34-7.36 (d, 1H, J = 10 MHz, quin-H6), 7.68-7.70 (td, 1H, J = 5 MHz, quin-H7), 7.90-7.94 
(m, 2H, quin-8 and quin-3), 8.00-8.01 (d, 1H, J = 5 MHz, quin-H5), 8.73-8.75 (d, 1H, J = 10 MHz, quin-
H4) 13C NMR (D2O, 125 MHz): δ 48.15, 51.72, 53.53, 54.68, 113.35, 119.28, 124.85,  128.62, 129.05, 
134.19, 134.80, 147.67, 148.57, 167.90, 174.38. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+ [M+H]+, 
528.3, found 528.4; calcd. for C25H39N9O42+, [M+2H]2+, 264.7, found 264.8; calcd. for C25H37N9NaO4+, 










Scheme 2-3. Synthesis of Eu-MP43 
 
N‐(quinolin‐3‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP38): Cyclen (1.001 g, 
5.80 mmol) and 2‐chloro‐N‐(quinolin‐3‐yl)acetamide (0.319 g, 1.45 mmol) were dissolved in CHCl3 (25 
mL). K2CO3 (0.243 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction 
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer 
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH 
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was dried with Na2SO4, 
filtered, and the solvent removed under reduced pressure to give a brown solid (0.460 g, 90%). 1H NMR 
(500 MHz, CDCl3):  2.70-2.75 (m br, 12H, NHCH2CH2NH), 2.84-2.86 (t br, 4H, J = 5 MHz, CH2NCH2), 
3.36 (s, 2H, NCH2C-quin), 7.47-7.51 (td, 1H, J = 5 MHz, quin-H6), 7.56-7.60 (td, 1H, J = 5 MHz, quin-
H7), 7.78-7.79 (d, 1H, J = 5 MHz, quin-H5), 7.98-7.99 (d, 1H, J = 5 MHz, quin-H8), 8.94-8.95 (d br, 1H, 
J = 5 MHz, quin-H4), 9.00-9.01 (d, 1H, J = 5 MHz, quin-H2). 13C NMR (125 MHz, CDCl3):  46.11, 46.17, 
47.46, 47.61, 53.93, 59.94, 122.89, 126.94, 127.81, 127.85, 128.39, 128.83, 132.15, 144.60, 144.93, 171.30. 
 
N‐(quinolin‐3‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP43): 2-bromoacetamide (0.525 g, 3.79 mmol), triethylamine (0.682 mL, 4.90 mmol) was 
added to a solution of MP38 (0.436 g, 1.22 mmol) in acetonitrile (25 mL). The mixture was stirred to reflux 
overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting tan solid (0.349 
g, 54 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.86-3.59 
(m, 22H, NCH2CH2N and CH2CH2C=O), 4.00 (s br, 2H, NCH2C-quin), 7.50-7.53 (m, 1H, quin-H6), 7.62-
7.65 (m, 1H, quin-H7), 7.69-7.71 (d, 1H, J = 10 MHz, quin-H5), 7.76-7.77 (d, 1H, J = 5 MHz, quin-H8), 







51.42, 54.35, 54.55, 54.98, 57.36, 124.84, 127.81, 127.93, 128.06, 128.42 130.56, 131.52, 140.54, 141.89, 
167.33, 168.00. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. for 




Scheme 2-4. Synthesis of Eu-MP44 
 
N‐(quinolin‐4‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP25): Cyclen (1.001 g, 
5.80 mmol) and 2‐chloro‐N‐(quinolin‐4‐yl)acetamide (0.320 g, 1.45 mmol) were dissolved in CHCl3 (25 
mL). K2CO3 (0.245 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction 
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer 
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH 
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was dried with Na2SO4, 
filtered, and the solvent removed under reduced pressure to give a brown solid (0.399 g, 77%). 1H NMR 
(500 MHz, CDCl3):  2.67-2.81 (m, 16H, NHCH2CH2NH), 3.41 (s, 2H, NCH2C-quin), 7.50-7.54 (td, 1H, 
J = 5 MHz, quin-H3), 7.66-7.69 (td, 1H, J = 5 MHz, quin-H7), 8.05-8.07 (d, 1H, J = 10 MHz, quin-H6), 
8.34-8.35 (d, 1H, J = 5 MHz, quin-H8), 8.40-8.42 (d, 1H, J = 10 MHz, quin-H5), 8.81-8.82 (d, 1H, J = 5 
MHz, quin-H2). 13C NMR (125 MHz, CDCl3):  46.07, 47.30, 47.38, 53.92, 60.87, 110.83, 120.39, 121.19, 
126.03, 129.27, 130.10, 140.73, 149.01, 151.20, 171.02. 
 
N‐(quinolin‐4‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP44): 2-bromoacetamide (0.460 g, 3.32 mmol), triethylamine (0.600 mL, 4.29 mmol) was 







overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting white solid 
(0.408 g, 72 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.90-
3.12 (m, 18H, NCH2CH2NCH2C=O), 3.87 (s br, 2H, NCH2C-quin), 4.09 (s br, 4H, NCH2C=O), 7.57-7.60 
(m, 1H, quin-H3), 7.83-7.86 (m, 1H, quin-H7), 7.92-7.93 (d, 1H, J = 5 MHz, quin-H6), 8.04-8.05 (d, 1H, J 
= 5 MHz, quin-H8), 8.21-8.22 (d, 1H, J = 5 MHz, quin-H5), 8.56-8.57 (d, 1H, J = 5 MHz, quin-H2). 13C 
NMR (D2O, 125 MHz): δ 48.33, 51.64, 54.27, 54.58, 55.50, 57.36, 110.43, 119.51, 122.04, 122.14, 128.72, 
133.87, 139.99,  145.36, 147.81, 168.19, 172.42. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 
528.3, found 528.4; calcd. for C25H39N9O42+, [M+2H]2+, 264.7, found 264.9; calcd. for C25H37N9NaO4+, 
[M+Na]+, 550.3, found 550.4. 
 
 
Scheme 2-5. Synthesis of Eu-MP45 
 
N‐(quinolin‐5‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP40): Cyclen (1.001 g, 
5.80 mmol) and 2‐chloro‐N‐(quinolin‐5‐yl)acetamide (0.319 g, 1.45 mmol) were dissolved in CHCl3 (25 
mL). K2CO3 (0.241 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction 
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer 
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH 
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was dried with Na2SO4, 
filtered, and the solvent removed under reduced pressure to give a pink solid (0.500 g, 96%). 1H NMR (500 
MHz, CDCl3): 2.66-2.80 (m, 16H, NHCH2CH2NH), 3.45 (s, 2H, NCH2C-quin), 7.39-7.42 (q, 1H, J = 5 
MHz, quin-H3), 7.68-7.71 (m, 1H, quin-H6), 7.92-7.94 (d, 1H, J = 10 MHz, quin-H7), 8.05-8.07 (d, 1H, J 
= 10 MHz, quin-H8), 8.69-8.71 (d, 1H, J = 10 MHz, quin-H4), 8.89-8.91 (dd, 1H, J = 5 MHz, quin-H2). 
13C NMR (125 MHz, CDCl3):  46.09, 46.13, 47.23, 47.46, 60.34, 120.46, 120.67, 122.50, 126.68, 129.35, 









yl]acetamide (MP45): 2-bromoacetamide (0.586 g, 4.25 mmol), triethylamine (0.770 mL, 5.48 mmol) was 
added to a solution of MP40 (0.488 g, 1.37 mmol) in acetonitrile (20 mL). The mixture was stirred to reflux 
overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting yellow solid 
(0.474 g, 66 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.46-
2.63 (m, 16H, NCH2CH2N), 2.90-2.93 (d, 6H, J = 15 MHz, NCH2C=O), 3.24 (s, 2H, NCH2C-quin), 7.36-
7.38 (m, 2H, quin-H3 and H6), 7.60-7.63 (m, 1H, quin-H7), 7.80-7.81 (d, 1H, J = 5 MHz, quin-H8), 8.04-
8.06 (d, 1H, J = 10 MHz, quin-H4), 8.67 (s, 1H, quin-H2). 13C NMR (D2O, 125 MHz): δ 52.24, 52.43, 
56.87, 57.14, 57.33, 58.17, 121.79, 124.22, 124.52, 124.58, 127.17, 129.74, 131.80, 132.18, 146.97, 147.00, 
150.47, 173.64, 176.78. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. 




Scheme 2-6. Synthesis of Eu-MP46 
 
N‐(quinolin‐6‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP39): Cyclen (1.000 g, 
5.80 mmol) and 2‐chloro‐N‐(quinolin‐6‐yl)acetamide (0.319 g, 1.45 mmol) were dissolved in CHCl3 (25 
mL). K2CO3 (0.242 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction 
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer 
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH 
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was dried with Na2SO4, 
filtered, and the solvent removed under reduced pressure to give a brown solid (0.467 g, 90%). 1H NMR 







NHCH2CH2NH), 3.33 (s, 2H, NCH2C-quin), 7.32-7.35 (q, 1H, J = 5 MHz, quin-H3), 7.79-7.82 (dd, 1H, J 
= 5 MHz, quin-H7), 7.98-8.00 (d, 1H, J = 10 MHz, quin-H5), 8.09-8.11 (d br, 1H, J = 10 MHz, quin-H8), 
8.51-8.52 (d, 1H, J = 5 MHz, quin-H4), 8.77-8.79 (dd, 1H, J = 5 MHz, quin-H2). 13C NMR (125 MHz, 
CDCl3):  45.88, 46.08, 47.27, 47.28, 53.77, 59.79, 115.50, 121.41, 123.30, 128.86, 129.95, 135.84, 136.34, 
145.43, 149.10, 170.59. 
 
N‐(quinolin‐6‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP46): 2-bromoacetamide (0.535 g, 3.87 mmol), triethylamine (0.700 mL, 5.00 mmol) was 
added to a solution of MP39 (0.445 g, 1.25 mmol) in acetonitrile (20 mL). The mixture was stirred to reflux 
overnight. A solid was formed, and the reaction mixture was vacuum filtered. The tan solid (0.427 g, 65 %) 
was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.93-3.50 (m br, 18H, 
NCH2CH2NCH2C=O), 3.66 (s br, 2H, NCH2C-quin), 4.06 (s br, 4H, NCH2C=O), 7.86-7.89 (m, 1H, quin-
H3), 7.94 (s br, 1H, quin-H7), 8.01 (s br, 1H, quin-H5), 8.32 (s br, 1H, quin-H8), 8.80 (s br, 1H, quin-H4), 
8.85-8.86 (d, 1H, J = 5 MHz, quin-H2). 13C NMR (D2O, 125 MHz): δ 48.47, 51.46, 54.52, 54.71, 55.26, 
57.35, 110.12, 116.52, 121.01, 122.04, 128.83, 129.60, 134.38, 138.36, 142.63, 146.64, 167.46. LRMS 
(ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. for C25H39N9O42+, [M+2H]2+, 




Scheme 2-7. Synthesis of Eu-MP47 
 
N‐(quinolin‐7‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP26):  Cyclen (1.001 g, 
5.80 mmol) and 2‐chloro‐N‐(quinolin‐7‐yl)acetamide (0.321 g, 1.45 mmol) were dissolved in CHCl3 (25 







mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer 
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH 
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was dried with Na2SO4, 
filtered, and the solvent removed under reduced pressure to give a brown solid (0.357 g, 67%). 1H NMR 
(500 MHz, CDCl3):  2.69-2.85 (m, 16H, NHCH2CH2NH), 3.32 (s, 2H, NCH2C-quin), 7.24-7.27 (q, 1H, J 
= 5 MHz, quin-H3), 7.70-7.72 (d, 1H, J = 10 MHz, quin-H6), 8.02-8.04 (d br, 1H, J = 10 MHz, quin-H8), 
8.11-8.14 (dd, 1H, J = 5 MHz, quin-H4), 8.28-8.29 (dd, 1H, J = 5 MHz, quin-H5), 8.80-8.82 (dd, 1H, J = 
5 MHz, quin-H2). 13C NMR (125 MHz, CDCl3):  45.88, 47.04, 47.15, 53.73, 59.85, 116.77, 119.81, 
120.51, 125.11, 128.39, 135.63, 139.63, 148.78, 150.71, 170.64. 
 
N‐(quinolin‐7‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP47): 2-bromoacetamide (0.699 g, 5.03 mmol), triethylamine (0.905 mL, 6.49 mmol) was 
added to a solution of MP26 (0.578 g, 1.62 mmol) in acetonitrile (20 mL). The mixture was stirred to reflux 
overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting orange solid 
(0.4786 g, 56 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.86-
3.62 (m, 22H, NCH2CH2NCH2C=O), 4.02 (s br, 2H, NCH2C-quin), 7.60-7.62 (d, 1H, J = 10 MHz, quin-
H3), 7.72-7.74 (t, 1H, J = 5 MHz, quin-H6), 7.99-8.01 (d, 1H, J = 10 MHz, quin-H8), 8.37 (s, 1H, quin-
H4), 8.79-8.81 (d, 2H, J = 10 MHz, quin-H5 and quin-H2). 13C NMR (D2O, 125 MHz): δ 48.51, 51.46, 
54.51, 54.84, 55.30, 57.34, 106.86, 120.07, 123.47, 126.01, 130.16, 138.58, 143.24, 143.71, 146.71, 167.95, 
171.67. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. for 
C25H39N9O42+, [M+2H]2+, 264.7, found 264.9; calcd. for C25H37N9NaO4+, [M+Na]+, 550.3, found 550.4. 
 
 








N‐(quinolin‐8‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP41): Cyclen (1.000 g, 
5.80 mmol) and 2‐chloro‐N‐(quinolin‐8‐yl)acetamide (0.322 g, 1.45 mmol) were dissolved in CHCl3 (25 
mL). K2CO3 (0.242 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction 
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer 
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH 
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was dried with Na2SO4, 
filtered, and the solvent removed under reduced pressure to give a white solid (0.380 g, 74%). 1H NMR 
(500 MHz, CDCl3):  2.68-2.78 (m, 13H, NHCH2CH2NH), 2.85-2.87 (t, 3H, J = 5 MHz, NHCH2CH2NH), 
3.39 (s, 2H, NCH2C-quin), 7.38-7.41 (q, 1H, J = 5 MHz, quin-H7), 7.38-7.51 (m, 2H, quin-H3 and quin-
H5), 8.09-8.11 (dd, 1H, J = 10 MHz, quin-H6), 8.74-8.75 (dd, 1H, J = 5 MHz, quin-H4), 8.85-8.86 (dd, 
1H, J = 5 MHz, quin-H2), 11.05 (s, 1H, NH). 13C NMR (125 MHz, CDCl3):  45.30, 45.52, 46.09, 46.76, 
52.94, 61.84, 116.85, 121.45, 121.81, 127.19, 128.14, 134.12, 136.22, 138.89, 148.42, 169.76. 
 
N‐(quinolin‐8‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP48): 2-bromoacetamide (0.420 g, 3.04 mmol), triethylamine (0.550 mL, 3.92 mmol) was 
added to a solution of MP41 (0.349 g, 0.980 mmol) in acetonitrile (20 mL). The mixture was stirred to 
reflux overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting white 
solid (0.375 g, 73%) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 
3.14-3.32 (m br, 18H, NCH2CH2NCH2C=O), 3.87 (s br, 6H, NCH2C-quin), 7.48 (s br, 2H, quin-H7 and 
quin-H3), 7.65 (s br, 1H, quin-H5), 8.05-8.06 (d, 1H, J = 5 MHz, quin-H6), 8.26 (s br, 1H, quin-H4), 8.70 
(s, 1H, quin-H2). 13C NMR (D2O, 125 MHz): δ 49.32, 50.70, 54.46, 54.99, 55.09, 57.36, 122.07, 122.30, 
125.35, 126.98, 128.48, 131.74, 138.52, 138.77, 149.23 167.26, 169.29. LRMS (ESI-MS): m/z calcd. for 
C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. for C25H39N9O42+, [M+2H]2+, 264.7, found 264.9; calcd. 
for C25H37N9NaO4+, [M+Na]+, 550.3, found 550.3. 
 
Metal Complexation  
Each ligand was dissolved in H2O (7 mL) and the pH of the solution adjusted to 6 using 0.3 M HCl. 
Equimolar amounts of aqueous EuCl3 was added, and the solution was stirred at room temperature 
overnight. The pH was raised to 10 by addition of 0.3 M NaOH to precipitate excess Eu3+ as Eu(OH)3. The 
precipitate was removed by syringe filtration, and the absence of free metal was confirmed using a Xylenol 








[Eu-MP30]: White solid. LRMS (ESI-MS): m/z calcd. for C24H36EuN8O32+, M2+, 318.6, found 
318.3. 
 
[Eu-MP42]: White solid. LRMS (ESI-MS): m/z calcd. for C25H37EuN9Na2O45+, [M3+ + 2Na]5+, 
145.2, found 145.2; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.  
 
[Eu-MP43]: Light golden tan solid, quantitative yield. LRMS (ESI-MS): m/z calcd. for 
C25H37EuKN9O43+, [M2+ + K]3+, 239.7, found 239.3; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0. 
 
[Eu-MP44]: White solid, quantitative yield. LRMS (ESI-MS): m/z calcd. for C25H37EuN9Na2O45+, 
[M3+ + 2Na]5+, 145.2, found 145.2; calcd. for C25H37EuKN9O43+, [M2+ + K]3+, 239.7, found 239.3.  
 
[Eu-MP45]: Golden brown solid. LRMS (ESI-MS): m/z calcd. for C25H37EuKN9O43+, [M2+ + K]3+, 
239.7, found 239.3; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.    
 
[Eu-MP46]: Golden brown solid. LRMS (ESI-MS): m/z calcd. for C25H37EuKN9O43+, [M2+ + K]3+, 
239.7, found 239.3; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.   
 
[Eu-MP47]: Golden brown solid. LRMS (ESI-MS): m/z calcd. for C25H37EuKN9O43+, [M2+ + K]3+, 
239.7, found 239.3; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.     
 
[Eu-MP48]: Light gold solid. LRMS (ESI-MS): m/z calcd. for C25H37EuN9O43+, M3+, 226.7, found 




 Absorbance spectra were acquired at room temperature over a 200-800 nm range using a 1.0 cm 
quartz cuvette and a 5 nm slit. Solutions of each lanthanide complex were prepared at 0.00625 mM in 0.1 
mM HEPES buffer (pH 7.4). 
 
 
Acquisition of Emission Spectra 
 
Solutions of each lanthanide complex were prepared at 0.1 mM using 0.1 mM HEPES buffer (pH 







temperature using a 1.0 cm quartz cell and an excitation monochromator slit width of 2 nm. Emission 
spectra were acquired from 570-750 nm. Each complex was excited at the maximum ex (Table 3).  
 
Table 2-1. Excitation wavelengths of each compound 
Compound Eu-MP30 Eu-MP42 Eu-MP43 Eu-MP44 
ex (nm) 319 325 328 354 
     
Compound Eu-MP45 Eu-MP46 Eu-MP47 Eu-MP48 




Acquisition of Excitation Spectra 
 
Solutions of each lanthanide complex were prepared at 0.1 mM using 0.1 mM HEPES buffer (pH 
7.4). A 450 nm long pass filter was used to eliminate second order peaks. Spectra were recorded at room 
temperature using a 1.0 cm quartz cell and an emission monochromator slit width of 2 nm. Excitation 
spectra of all complexes were acquired from 200-450 nm. Each spectrum was acquired with the em 
indicated in Table 4. 
 
Table 2-2. Emission wavelengths of each compound 
Compound Eu-MP30 Eu-MP42 Eu-MP43 Eu-MP44 
em (nm) 636 635 635 635 
     
Compound Eu-MP45 Eu-MP46 Eu-MP47 Eu-MP48 





   
Phosphorescence decay by delay measurements were acquired using a flash count of 50, sample 
window of 0.2 ms, 0.05 ms delay increment, 5 ms max delay, and an initial delay of 0.05 ms. Samples were 
prepared by lyophilizing aliquots of each lanthanide solution in 500 L of 0.1 mM HEPES buffer (pH 7.4). 
One aliquot of each lanthanide solution was then redissolved in D2O and lyophilized. These samples were 
dissolved once more in D2O and lyophilized. Solutions at 0.02 mM concentration were made by dissolving 
the compounds in HEPES buffer or D2O. The data was fit with a mono-exponential decay function to obtain 
 values. The number of bound water molecules (q) was determined using equation 1 where x represents 








      𝑞𝐸𝑢 = 1.2[(𝑘𝐻2𝑂 − 𝑘𝐷2𝑂) − 0.25 − 0.075𝑥]              (1) 
       
 
Quantum Yield ( ) Measurements 
 
Absorbance spectra were acquired over a 200-800 nm range and at room temperature, using a 1.0 
cm quartz cuvette and a 5 nm slit width. Solutions of each lanthanide complex were prepared using 0.1 mM 
HEPES buffer (pH 7.4) such that their absorbance intensities at 315 nm fell between 0.005 and 0.05. 
Emission spectra were acquired upon excitation at 315 nm from 570-750 nm. Areas under the emission 
curves versus absorbance intensities at 315 nm were graphed and fit with a linear equation. These plots 
were compared with data acquired in a similar manner for reference compounds with known quantum yields 
[Rhodamine 101 in ethanol ( = 1)].25 Equation 2 was used to determine the quantum yield value of each 
complex where R denotes values corresponding to the reference compound, x corresponds to the unknown 
sample measurements, m represents the slope from the linear fit of the area under the emission curve versus 
absorbance intensity, and n is the refractive index of the solvent used.26 
 











Kinetic Stability Measurements  
 
 Each complex was diluted to 0.1 mM with 10 mM citrate buffer at pH 3 and stored in a quartz 
cuvette at 21 oC and in a hot water bath at 37 oC. The emission intensities at 615 nm were monitored over 
7 days at 21 oC, and over 48 h at 37 oC. The resulting emission data was plotted as a function of time and 













Absorption spectra were acquired for each complex to evaluate how differences in the quinoline 
antenna affect the photophysical properties of the library of Eu3+ complexes. To this end, absorption in the 
250-350 nm range was analyzed as this is the region in which  → * and n → * transitions are typically 
observed for quinoline compounds.27,28 Normalized absorption spectra for all complexes are shown in 
Figure 2-4.  
 
Figure 2-4. Normalized absorbance spectra of 0.0625 mM solutions of each complex prepared in 0.1 mM 
HEPES buffer (pH 7.4). Spectra were obtained at room temperature from 200-800 nm. 
 
 
The absorption spectra of all compounds in this study exhibit similar broad peaks, with the lowest 
energy peaks between 300 and 340 nm. These peaks can be attributed to  → * transitions for the quinoline 
side-chains.28 The max values are slightly different for each compound. This suggests that changes in the 
positions of the amide substituents relative to the quinoline nitrogen do affect the maximum energy that can 
be absorbed by the quinoline antenna. 
 
Analysis of Excitation Spectra 
 
Through acquisition of the excitation spectra, one can evaluate the amount of energy required to 
excite an electron from the singlet ground state to the singlet excited state on the quinoline chromophore.6 




























Following intersystem crossing from the singlet excited state to the triplet excited state of the ligand, some 
of the energy absorbed by the ligand will be transferred to the Ln3+ excited states. The sharp emission lines 
from the metal center are typically observed following rapid internal conversion to the emitting level of the 




Figure 2-5. Normalized excitation spectra of all complexes prepared at 0.1 mM with 0.1 mM HEPES 
buffer (pH 7.4). Spectra were acquired at room temperature from 200-450 nm with an emission 
monochromator slit width of 2 nm. em values used to acquire each spectrum and maximum wavelengths 
of excitation can be found in Table 2-3.   
 
 
Table 2-3. Peak emission and excitation wavelengths of each complex ( 2 nm). 
 
Complex em ex 
Eu-MP30 636 319 
Eu-MP42 635 325 
Eu-MP43 635 328 
Eu-MP44 635 354 
Eu-MP45 635 314 
Eu-MP46 634 325 
Eu-MP47 634 326 
Eu-MP48 635 312 
 
The maximum excitation wavelengths are reflective of  → * electronic transitions in each ligand 
and vary from largest energy (312 nm) for Eu-MP48 to smallest energy (354 nm) for Eu-MP44.28 There 
may be slightly higher conjugation in Eu-MP44 brought about by the quinoline amide being in the para-





























substituted position relative to the nitrogen atom in the ring. The para position allows for overlap between 
the p-orbitals of nitrogen on the quinoline ring and the amide substituted carbon. The overlap between these 
orbitals leads to a higher conjugation of the molecule, which allows for a greater delocalization of the 
electrons.29 The higher conjugation of this compound leads to a smaller energy gap between the →* 
electronic transition. The smaller energy gap results in a longer wavelength due to the relationship between 
energy and wavelength. This means that lower energy is required to promote electrons from the singlet 
ground to singlet excited state of the ligand.30 
Evaluation of Emission Properties 
The emission spectra of all complexes display characteristic Eu3+ centered emission properties 
(Figure 2-6). Narrow emission bands from 5D0 – 7FJ,where J = 0 – 4, are observed between 598 – 717 nm, 
with the most intense emission band located at approximately 615 nm.31  
 
 
Figure 2-6. Emission spectra of 0.1 mM complexes prepared in 0.1 mM HEPES buffer (pH 7.4). Spectra 
were acquired at room temperature from 570-750 nm with an excitation monochromator slit width of 2 
nm. ex values can be found in Table 2-3. 
 
 
 Eu-MP30 possessed the highest emission intensity of all compounds. A shortened distance between 
the directly coordinated quinoline chromophore and the lanthanide center could allow for more efficient 
sensitization of the lanthanide’s luminescence.3 All other complexes displayed emission intensities that 


































varied based on the location of the amide on the quinoline sidearm, with Eu-MP42 having the highest 
emission intensity and Eu-MP48 having the lowest intensity. The difference in amide substituent location 
on the quinoline antenna may result in increased rigidity of some of the compounds. Increased rigidity could 
potentially minimize energy loss via X-H vibrations, which could result in an increase in emission intensity 
due to reduced quenching.15 Another potential cause for the differences in emission intensity may lie in the 
mechanism for sensitizing the lanthanide ion through pendant antenna, the Förster resonance energy 
transfer.10 This mechanism is reliant on the dipole-dipole coupling between the longitudinal relaxation of 
the antenna and the energy of the 4f orbitals of the lanthanide, and depends upon the distance r between the 
antenna and the lanthanide ion, with an efficiency 1/r6. It is possible that the changes in the location of the 
amide substituent impacts the energy transfer mechanism by altering the distance between the europium 
ion and the quinoline antenna, thus resulting in a change in emission intensity.   
 
The emission bands in a Eu3+ spectrum can also be used to draw conclusions about the symmetry 
of the compound. In particular, the J = 0 and J = 2 bands at 590 nm and 615 nm, respectively, can indicate 
structural properties.8 The J = 0 band located at approximately 590 nm is typically a weak, forbidden band 
in most Eu3+ complexes as explained by the Judd-Ofelt theory.8 This band can be seen at a relatively high 
intensity in all of the metal complexes. This sharp appearance of the J = 0 emission band implies that the 
Eu3+ ion occupies a site with Cnv, Cn, or Cs symmetry.8 The J = 2 band at 615 nm is known as the 
hypersensitive transition, and its intensity is also heavily influenced by the local symmetry of the lanthanide 
ion.32,33 Higher asymmetry of the complex leads to a higher emission intensity.34,35 Higher asymmetry of 
the ligand field makes the forbidden f-f transitions somewhat more allowed by modifying the interaction 
between the inner 4f-shell of the Eu3+ ion with its environment.36,37 Asymmetry enhances the luminescence 
of the complex by reducing the nonradiative decay rate and increasing the probability of radiative 
emission.38 The ratio of the intensities between this band and the J = 1 band are used to measure the 
asymmetry of the Eu3+ site. The higher the intensity ratio, the more asymmetric the metal complex.8 These 
ratios are summarized in Table 2-4.  
 
Eu-MP30, Eu-MP43, Eu-MP46, and Eu-MP47 have the same ratio which indicates these 
complexes have very similar symmetry. Eu-MP44 has the highest ratio of 1.87 and therefore is assumed to 
have the most asymmetry of all the compounds. Although this does not seem to impact its emission intensity 
as the intensity of Eu-MP44 falls between those of the other compounds, but it may be responsible for the 
lower energy of excitation. Eu-MP45 and Eu-MP48 have the lowest intensity ratios, showing these 
compounds are more symmetric than the other Eu3+ complexes. The higher symmetry of these complexes 








Table 2-4. Ratio of intensities of the J = 1 and J = 2 bands of the Eu3+ emission spectra. 
 
Compound J = 1 Intensity J = 2 Intensity Ratio I2/I1 
Eu-MP30 3050000 3860000 1.27 
Eu-MP42 1210000 1680000 1.39 
Eu-MP43 757800 964210 1.27 
Eu-MP44 669280 1250000 1.87 
Eu-MP45 182950 298500 1.08 
Eu-MP46 1120000 1420000 1.27 
Eu-MP47 1180000 1490000 1.26 




Figure 2-7. Comparison of areas under the emission spectra upon excitation of the quinoline antenna 




Free lanthanide ions on their own do not display adequate luminescent capabilities due to forbidden 
4f-4f transitions and low molar absorptivity coefficients ( < 1 M-1cm-1).10,39 To overcome this limitation, 
an organic chromophore (antenna) is typically used to aid in the sensitization of the lanthanide’s 
luminescence. Figure 2-7 shows a comparison of the emission intensities upon excitation of the antenna on 

























































































results in 2 – 10000-fold higher emission intensities compared to direct excitation of the lanthanide ion. 
Even Eu-MP48, with the lowest emission intensity overall, displays a 2-fold increase in the magnitude of 
the emission intensity in comparison to direct excitation of the Eu3+ ion. This indicates that antenna 




Figure 2-8. From left to right, Eu-MP30, Eu-MP42, Eu-MP43, Eu-MP44, Eu-MP45, Eu-MP46, Eu-
MP47, and Eu-MP48 (1E-4 M) in 0.1 M MES buffer (pH 7.5). All compounds were excited using a UV 
light source at 302 nm except Eu-MP44 that was excited at 365 nm.  
 
  
Upon irradiation with a UV lamp, most compounds display the red color characteristic of Eu3+ 
complexes (Figure 2-8), and it is visible to the naked eye. Excitation at 365 nm is not optimal for all of the 
complexes, thus the brightness observed does not directly correlate with the measured emission intensity 
(Figure 2-6). However, all complexes aside from Eu-MP48 and Eu-MP45 emit red light upon excitation at 
this longer wavelength. The ability to excite the complexes at longer wavelength allows for the use of lower 
energy light sources which will potentially be less damaging to biological tissue. 
 
Determination of Quantum Yield Values 
Quantum yield is a measure of the ratio of emitted photons to absorbed photons.40 It is therefore a 
measurement of the probability that an excited photon will emit light as it relaxes to equilibrium. The overall 
quantum yield also takes into account the energy transfer efficiency from the antenna to the lanthanide ion. 
Quantum yields were determined using previously published methods.26 The calculated quantum yield 









Table 2-5. Calculated quantum yield and brightness values of Eu3+ complexes prepared in 0.1 mM 
HEPES buffer (pH 7.4) using Rhodamine 101 in ethanol ( = 1)25 as a reference at 315 nm. 
 
Compound Quantum Yield () 
Molar Absorptivity 
Coefficient () (M-1 cm-1) 
Calculated B 
Eu-MP30 0.0272 7160 195 
Eu-MP42 0.0040 5100 20.4 
Eu-MP43 0.0043 5730 24.6 
Eu-MP44 0.0028 5070 14.2 
Eu-MP45 0.0022 7650 16.8 
Eu-MP46 0.0091 2910 26.5 
Eu-MP47 0.0105 5210 54.7 
Eu-MP48 0.0005 5460 2.73 
 
Eu-MP30, the complex with the directly coordinated quinoline sidearm, exhibited the highest 
quantum yield of all synthesized complexes. This is attributed to the close distance between the quinoline 
antenna and the lanthanide center allowing for better sensitization of the lanthanide ion’s luminescence 
through the Förster mechanism.9 This observation was also consistent with Eu-MP30 displaying the highest 
emission intensity. Eu-MP48 exhibited the lowest quantum yield, and this was well correlated to its very 
low emission intensity. The quantum yields of all compounds in this study ranged from 0.05 – 2.72%. 
Previous studies on Eu3+ complexes have reported similar quantum yield values, with compounds 
containing directly coordinated antennae having quantum yields of 3.9 – 6%, and those with indirectly 
coordinated antennae yielding values of 1.4 – 6.2%.41,42 
 
In the development of agents for optical imaging of biological tissue, it is important to design 
compounds with high quantum yields. This helps to ensure adequate brightness of the agent, which is 
important for proper visualization of tissue. The relationship between brightness and quantum yield is 
shown in equation 3 where  is the molar absorptivity coefficient of the antenna and  is the luminescence 
quantum yield.43 This direct relationship between brightness and quantum yield supports the correlation 
between the low quantum yields calculated for Eu-MP48 and Eu-MP45 and visible brightness. Calculated 
brightness values can be found in Table 2-5.   
 
𝐵 = 𝜀Φ       (3) 
 
 
Singlet and Triplet State Energies 
As previously mentioned, enhanced sensitization of the luminescence of the Eu3+ ions involves the 







internal conversion to the emitting level of the lanthanide, light is emitted as sharp emission bands 
characteristic of Eu3+.6,7,8 For efficient energy transfer to occur, the energy gap between the triplet state of 
the ligand and the emissive level of the lanthanide ion should be greater than 2500 cm-1, while being less 
than 3500 cm-1.13 This ensures that the energy gap is large enough to overcome back energy transfer while 
being small enough to allow for efficient energy transfer to occur.  
 
To estimate the singlet and triplet energy levels of the synthesized ligands, steady-state 
fluorescence and time-resolved phosphorescence spectra were acquired of their corresponding Gd3+ 
complexes. Gd3+ is used in these measurements because its electronic levels are too high in energy to 
participate in transfer from the quinoline antennae used in this study.44,45 Using the maximum wavelength 
of the emission spectra for both fluorescence and phosphorescence measurements, the energy of the singlet 
and triplet states for each compound could be ascertained. The calculated singlet and triplet state energies 
for each complex can be seen in Table 2-6.  
 
Table 2-6. Singlet and triplet state energies for each complex. Singlet energies were acquired through 
fluorescence measurements at room temperature. Triplet energies were obtained through phosphorescence 
emission spectra at 77 K. E refers to the energy difference between the triplet excited state of the ligand 
and the excited state of the Eu3+ ion. 




Gd-MP30 26300 19600 2400 
Gd-MP42 26200 19800 2600 
Gd-MP43 24200 19100 1900 
Gd-MP44 26200 19100 1900 
Gd-MP45 21900 18100 900 
Gd-MP46 19400 19100 1900 
Gd-MP47 20000 19300 2100 
Gd-MP48 21600 17600 400 
 
 Upon comparison of the triplet energies of each ligand to that of the 5D0 radiative excited state of 
the Eu3+ ion, all complexes except Gd-MP42 were found to have energy gaps lower than the optimum 2500 
cm-1 between the triplet excited state of the ligand and the 5D0 energy level of the Eu3+ ion.46–48 Gd-MP45 
and Gd-MP48 exhibited the lowest triplet state energies of all of the compounds, with E values of 900 and 
400 cm-1, respectively. This small energy gap enables back energy transfer from the lanthanide ion to the 
ligand much more easily, 13 and provides the best explanation for the low emission intensities and quantum 







between the triplet state of the ligand and the radiative excited state of Eu3+, corresponding to their Eu3+ 
complexes displaying higher emission intensities. Although Eu-MP30 was shown to have the highest 
quantum yield of all of the Eu3+ compounds, Eu-MP42 had only the 5th highest quantum yield value, 
suggesting that other factors besides the triplet state energy levels could be playing a role in the measured 
quantum yield of this complex. All other complexes displayed E values between 1900 – 2100 cm-1 
consistent with their Eu3+ complexes having lower intensities and quantum yield values due to some amount 
of back energy transfer.  
Evaluation of Luminescence Lifetimes and Determination of q-values 
 Lanthanide ions such as Eu3+ exhibit long-lived luminescence lifetimes that make them ideal for 
time-resolved detection. These long-lived luminescence lifetimes allow for the acquisition of signal after 
background autofluorescence has subsided.49,50 Using luminescence lifetimes, the number of bound water 
molecules can be calculated through comparison of the luminescence signal decay in both D2O and H2O. 
Water quenches luminescence intensity due to its O-H oscillating groups while the O-D oscillator in D2O 
has negligible effects.7 This allows for the rates of decay in each solvent to be related to the number of 
lanthanide-bound water molecules through the Horrocks equation (equation 4) where x is the number of 
amide protons in each complex.24 The measured luminescence lifetime values for each compound and their 
calculated q values can be found in Table 2-7.  
 
𝑞 = 1.2[(𝑘𝐻2𝑂 − 𝑘𝐷2𝑂) − 0.25 − 0.075𝑥]    (4) 
 
 
Table 2-7. Lifetime measurement and q values of 0.02 mM complexes in 0.1 mM HEPES buffer (pH 7.4) 
and D2O. 
Compound  D2O (ms)  H2O (ms) k D2O (ms-1) k H2O (ms-1) q-value 
Eu-MP30 1.93 0.504 0.519 1.98 0.916 
Eu-MP42 0.893 0.417 1.12 2.40 0.602 
Eu-MP43 0.358 0.213 2.79 4.69 1.35 
Eu-MP44 0.532 0.293 1.88 3.42 0.915 
Eu-MP45 0.152 0.133 6.57 7.55 0.239 
Eu-MP46 0.623 0.301 1.61 3.32 1.12 
Eu-MP47 0.682 0.325 1.47 3.08 1.00 
Eu-MP48 0.611 0.292 1.64 3.42 1.21 
 
 As expected, the luminescence lifetime of each complex in water is shorter than that in D2O. This 







all compounds display luminescence lifetimes in D2O that are at least 2-fold greater than the lifetimes in 
H2O. Eu-MP45 has lifetimes that are nearly identical in D2O and H2O. The calculated q values are indicative 
of one bound water molecule on each complex except for Eu-MP45. These q values are consistent with 
Eu(III) having nine coordination sites, eight of which are occupied by the donor atoms of the octadentate 
ligands used in this study, and the ninth occupied by one bound water molecule.51 The method used to 
estimate q values does exhibit an error of 0.5 and could be a possible explanation for the lower q value 
measured for Eu-MP45.  
 
Effect of pH on Luminescence Properties 
Lanthanide complexes can be designed to be responsive to pH, a feature that could potentially be 
used to detect pathological conditions that exhibit altered tissue pH.52 To evaluate the effect of pH on 
emission and excitation properties, each compound was incubated at pH values ranging from 5.5 – 8.5. 
Change in emission intensity of the hypersensitive band as a function of pH can be seen in Figure 2-9 
respectively.  
 
Figure 2-9. Ratio of emission intensity at 614 nm and 592 nm versus pH. Samples were prepared at 0.1 
mM in 0.1 M MES buffer (pH 5.5 and 6.5) and 0.1 M TRIS buffer (pH 7.5 and 8.5) with 0.1 M KCl. 
Emission spectra were acquired at room temperature from 570-750 nm.  
 
All complexes displayed an increase in the J = 2 (614 nm) to J = 1 (592 nm) emission intensity 
ratio as pH was increased. Previous work by Woods and coworkers showed a similar trend which was 
attributed to a combination of the deprotonation of the lanthanide-bound water molecule above pH 7, and 































deprotonation of the amide group brought about by an acceleration of proton exchange at higher pH.53,54 
The deprotonation of the amide would result in an increase in Eu3+ emission intensity due to a reduction in 
the quenching effect of the closely oscillating amide protons.  
 
Evaluation of Kinetic Stability  
Evaluation of a compound’s kinetic stability is important to establish safety for use in vivo. Free 
lanthanide ions pose a risk of heavy metal poisoning but when strongly chelated, pass through the body 
intact.55 Previous studies showed that the stability of lanthanide complexes can be evaluated by monitoring 
signal changes brought about by ligand exchange,56 transmetallation,57 or proton-assisted dissociation.58–60 
To evaluate the kinetic stabilities of the library of compounds in this study, proton-assisted dissociation was 
used wherein all compounds were incubated in acidic buffer, and their emission intensities monitored over 
time. For complexes with low kinetic stabilities, their metal ions should be easily displaced by protons in 
the buffer thus increasing their distance from the chromophore. The resultant effect would be a reduction 
in emission intensity as the ability of the antenna to sensitize the emission intensity decreases. Plots of the 
emission intensities of each compound at 21.4 oC and 37.8 oC are shown in Figure 2-10. Dissociation half-
lives were calculated by fitting the data to mono-exponential decay or linear functions (Table 2-8). Half-
life values marked with an asterisk may not be indicative of the true value of stability due to the inability 









Figure 2-10. Plot of emission intensity at 615 nm over (A) 7 days at 21.4 oC and (B) 48 h at 37.8 oC. 
Samples were prepared at 0.1 mM with 10 mM citrate buffer at pH 3. Emission measurements were 
acquired from 570-750 nm with a slit width of 2 nm. Each data set was fit with a mono-exponential decay 
fit (dashed line). 



















































































Table 2-8. Calculated half-life values at 21.4 oC and 37.8 oC. 
 
Compound Half-life 21.4 C (h) Half-life 37.8 C (h) 
Eu-MP30 2.79 0.510 
Eu-MP42 136 26.8 
Eu-MP43 65600* 74.2* 
Eu-MP44 32.92 4.08 
Eu-MP45 1240* 118* 
Eu-MP46 507* 68.3* 
Eu-MP47 308* 66.4 
Eu-MP48 ** 99.3* 
 
* Calculated using linear fit instead of mono-exponential decay fit. 
** Unable to be calculated as the emission intensity did not decrease over 
the testing period. 
 
All compounds show greater half-life values at lower temperatures by at least 4-fold. This was to 
be expected as increasing temperature usually causes an acceleration of reaction rates; in this particular 
case, it results in a faster dissociation of the metal ion from the complex.61 As shown in Figure 2-10, Eu-
MP30 shows the poorest stability at both temperatures as its emission intensity decays completely after one 
day at 21.4 oC and in less than 5 h at 37.8 oC. Eu-MP42 and Eu-MP44, also appear to dissociate quickly at 
37.8 oC, with half-life values of 26.8 and 4.08 h, respectively. All other compounds exhibited higher 
stability as their half-lives were greater than 60 h at higher temperatures. Eu-MP48 initially showed an 
increase in emission intensity after 24 h at 21.4 oC, after which its emission intensity stayed relatively 




 Lanthanide-based complexes have the potential to act as bimodal agents for MRI and optical 
imaging. The long-lived luminescence lifetimes of Eu3+ can be utilized to overcome the limitations of 
traditional optical imaging probes such as autofluorescence. This study evaluated the effect of the amide 
position of quinoline antennae on the luminescence properties of a series of Eu3+ complexes. It was found 
that the amide substituent on the aminoquinoline antenna does affect the luminescent properties as well as 
the stability of each of the compounds. This is possibly due to changes in the pi-system of each antenna 
brought about by the location of the amide substituent relative to the nitrogen in the ring. While Eu-MP30 







compound’s emission signal decayed at the fastest rate under acidic conditions, thus indicating poor kinetic 
stability. The direct coordination of the quinoline antenna to the Eu3+ metal center showed the highest 
sensitization of the lanthanide’s luminescence due to the shorter distance between the antenna and the 
lanthanide ion. In contrast, Eu-MP48 and Eu-MP45 had emission signal that remained stable under acidic 
conditions, indicating good kinetic inertness, but displayed the lowest emission intensity and quantum yield 
values of all the complexes. The position of the nitrogen on the aminoquinoline antenna for Eu-MP45 and 
Eu-MP48 resulted in a smaller energy gap between the triplet energy level of the ligand and the emissive 
level of the lanthanide ion. The smaller energy gap may have resulted in substantial back energy transfer 
that led to the low emission intensity of these two complexes. For in vivo applications, the ideal optical 
imaging agent should possess high quantum yield and high stability. Of all the complexes in this study, Eu-
MP43, Eu-MP46, and Eu-MP47 exhibit a reasonable balance of these two features, with quantum yields 
between 0.0043 – 0.0105 and dissociation half-lives above 48 h at 37.8 oC. These features make these 
complexes the most promising for future studies.  Additionally, all complexes were found to have one 
bound water molecule, which is a necessary feature for the generation of MRI contrast through water proton 
exchange. Future work will include performing energy calculations to better understand the correlation 
between amide position on the aminoquinoline antenna and luminescence properties, and evaluation of the 
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Chapter 3. Effects of Antenna and Side-Chain Identities on the Optical and 




The MR and optical properties of Ln(III) complexes are significantly influenced by several factors 
that include ligand structure, metal ion identity, and the number of bound water molecules. Systematic 
variation and investigation of these factors in a complex allows for a better understanding of their effects 
on its MR and optical features. The goal of this study was to evaluate the effect of varying ligand side-
chains on the MRI and optical properties of europium and terbium complexes. To this end, three pyridine- 
and quinoline- containing ligands were synthesized and characterized. Their respective Tb(III) and Eu(III) 
complexes were prepared, and the luminescence and PARACEST MRI properties evaluated. Results 
showed that emission intensities and quantum yield values varied with ligand side-chain and metal ion 
identities while the excitation and absorption properties remained largely unaffected. All complexes were 
estimated to have one coordinated water molecule, the presence of which allowed the observation of a 
PARACEST effect for the Eu(III) complexes. Preliminary CEST studies of the pyridine-containing Eu(III) 
complexes showed a variation in CEST signal with different side-chains. The metal complexes with more 
amide protons exhibited the broadest CEST peaks and largest CEST signals while complexes with 
carboxylate groups showed sharp and less intense CEST peaks. The CEST signal of the aspartate-containing 
complex was also found to increase at higher temperatures, which may indicate more optimal exchange 













 Paramagnetic Chemical Exchange Saturation Transfer (PARACEST) agents represent an 
alternative class of MRI contrast agents that utilize the chemical exchange of labile and bulk water protons 
to generate contrast.1 Typical agents are lanthanide ions, other than Gd3+, chelated with an octadentate 
ligand such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraamide (DOTA-tetraamide).2 The fast water 
water exchange kinetics, and excellent T1-shortening properties of Gd3+ agents are highly detrimental for 





Figure 3-1. An example PARACEST agent with a DOTA tetraamide ligand. The Ln3+ is any lanthanide 
ion besides Gd3+.  
 
 
 PARACEST agents have some notable advantages over typical Gd(III) based contrast agents. One 
such advantage is that they can be turned “on” and “off” with the application of a selective radiofrequency 
pulse, which could potentially shorten the time needed to acquire a complete MRI scan.3 PARACEST 
agents can also be designed to be responsive to changes in chemical environments such as pH and oxidative 
stress.4 Acidic pH is a common biomarker used to characterize tumor microenvironments.5 Needle biopsy 
can typically be used to measure the pH of surface accessible tumors, but MRI would be a noninvasive 
approach that could be used to assess tumors at any location in the body.6 Changes in redox environments 
can also be indicative of pathophysiological conditions such as ischemia.7 The ability to use MRI to better 
detect minute changes in redox environment could help in better diagnosis of potentially fatal conditions.  
 
An additional advantage of PARACEST agents is that their MRI signal has the potential to be 
concentration independent by applying ratiometric methods, which involve using a non-responsive 







monitoring the CEST properties of two magnetically different CEST sites.9,10 One site shows dependency 
on the variable of interest while the other site is not affected.11 The ratio of the bulk water signal from the 
two pools provides information of the variable of interest without necessitating knowledge of the exact 
concentration of contrast agent.11 While in vitro studies of PARACEST agents have shown potential for 
improved medical diagnosis, their translation in vivo has been limited due to signal losses caused by a 
phenomenon called T2 exchange.   
 
 
The T2 Exchange Mechanism 
The T2 exchange (T2ex) effect is a relaxation process that causes a local decrease in the bulk water 
signal similar to the contrast provided by PARACEST agents.12 This effect has been found to occur through 
the same slow-to-intermediate exchange of labile protons and/or inner-sphere water molecules with bulk 
water that is characteristic of PARACEST agents.12   
 
 
Figure 3-2. MR images of healthy mouse kidneys displaying T2ex contrast due to a 0.5 mmol/kg 
intravenous dose of a PARACEST agent at 37 oC (a-c) and 25oC (d-f); (a,d) kidneys pre injection; (b,e) 
kidneys post injection, (c,f) pre minus post.13  
 
 
The T2ex process causes a severe darkening of an MR image upon injection of a PARACEST agent 
(Figure 3-2). This darkening occurs post injection without the need to “turn on” the PARACEST agent with 
a selective radiofrequency pulse; and is more pronounced at physiological temperatures.12,13 Although this 
competing T2ex mechanism has been viewed as a new source of MRI contrast, discrimination between MR 
image darkening caused by T2ex and that caused by the CEST effect presents a significant problem that 








Several researchers have attempted to overcome the loss of signal intensity caused by the T2ex 
mechanism. These studies focused on utilizing optimum exchange rates and imaging sequence parameters. 
Soesbe et al. showed that the PARACEST and T2ex contrast mechanisms reach maximum signal intensities 
at different exchange rates and have suggested selecting an exchange rate that maximizes the PARACEST 
signal while minimizing the T2ex signal.13 This group also suggested using imaging agents with slow-to-
intermediate water exchange at lower magnetic fields where T2ex is less prominent.13 The lower magnetic 
field, combined with a novel pulse imaging sequence utilizing short echo times (TE) and sweep imaging 
with Fourier transform (SWIFT) pulse sequencing, enabled PARACEST MR imaging with little 
interference from T2ex.13 The use of short TEs allowed the detection of short T2 components as normal echo 
times were not short enough to capture MR signal from regions of reduced T2 caused by PARACEST 
agents.13 This study highlighted the promise of using PARACEST agents in vivo upon elimination of the 
T2ex effect.  
 
In another study, Soesbe and coworkers investigated the T2ex properties of three Eu3+ complexes, 
EuTETA-, EuDOTA-(gly)4-, and EuDOTA-, that exhibit very slow, slow-to-intermediate, and fast water 
exchange, respectively.12 EuTETA- (very slow exchange) and EuDOTA- (fast exchange) only displayed 
slight darkening of the renal pelvis during renal clearance 30 minutes post injection, while EuDOTA-(gly)4- 
(slow-to-intermediate exchange) showed dramatic darkening of the kidneys and surrounding tissue post 
injection (Figure 3-3).12 These results suggest that designing PARACEST agents that exhibit fast water 




Figure 3-3. MR images of healthy mouse kidneys before and after 0.25 mmol/kg intravenous injection of 
(a) EuDOTA-, (b) EuDOTA-(gly)4-, and (c) EuTETA-. Post injection images of those agents with no 
exchange and fast exchange (a, c) show little darkening of the renal veins while the agent with slow-to-









Lanthanide Coordination Geometries 
As previously mentioned, typical PARACEST agents comprise a lanthanide ion chelated with a 
ligand such as DOTA-tetraamide, which is known to form thermodynamically stable and kinetically inert 
complexes with lanthanide ions.1,2,15,16 This can be attributed to a properly sized cavity in the ligand to 
adequately fit lanthanide ions.17 DOTA-tetraamide ligands are also octadentate, allowing the lanthanide ion 
to bind to 8 sites on the ligand with one site available to bind one water molecule.18 
 
In solution, DOTA-based Ln(III) complexes form two isomers that adopt the monocapped square 
antiprism (SAP) and monocapped twisted square antiprism (TSAP) geometries.19 These isomers can 
interconvert through pendant arm rotation or ring flipping to form two diastereomers that form 
enantiometric pairs (Figure 3-4).19 The enantiometric pairs are denoted as (), () and (), 
() where  and  refer to an arm rotation clockwise and counterclockwise, respectively, while  
and  refer to clockwise and counterclockwise ring helicities, respectively. The latter pair of 
enantiomers have TSAP geometry while the former pair have SAP geometry.18  
 
 
Figure 3-4. Isomer geometries of typical DOTA complexes. Interconversion between SAP and TSAP 








The differences in conformation due to each isomer geometry results in distinct properties for the 
lanthanide complex. TSAP isomers have a more open structure due to the twisting about their metal center 
while SAP isomers have a more compact, rigid structure.21 Due to its expanded structure, TSAP isomers 
exhibit longer coordination bonds between the Ln3+ ion and the bound water.21 This allows for water 
exchange rates that are up to 50 times faster than that of SAP isomers.20,22,23 For typical PARACEST 
applications that rely on the generation of contrast through slow-to-intermediate exchange of bound water 
molecules, SAP isomers are preferred because the water exchange of TSAP isomers is too fast to observe 
the CEST effect.24 However, CEST can also occur between bulk water protons and -NH or -OH protons 
bound to the PARACEST agent, and the CEST signal that arises from the amide or hydroxyl protons can 
be detected for both the SAP and TSAP isomers.25 In this case, complexes with rapidly exchanging bound 
water molecules are preferred so that there is no loss of signal due to T2ex.3  Hence, the design of 
PARACEST agents that preferentially adopt the TSAP geometry in solution and can produce a CEST signal 
through exchange of amide or hydroxyl protons could result in complexes that exhibit fast enough bound 
water exchange kinetics to overcome the aforementioned T2ex mechanism.  
 
The incorporation of lanthanide ions such as Tm3+ in complexes that primarily adopt the TSAP 
geometry in solution results in narrower line widths in PARACEST spectra, which corresponds to increased 
sensitivity.26 As seen in Figure 3-5, a CEST signal from the TSAP isomer of a Tm3+ DOTA-tetraamide 
complex is much greater than that of the SAP isomer and has a larger chemical shift. Fast water exchange 
kinetics associated with the TSAP isomer can often cause a broadening of signal, but use of lanthanide ions 




Figure 3-5. Plots showing the CEST chemical shifts of amide pools of Tm3+ DOTAM complexes of both 








Previous studies have established that the SAP/TSAP isomer ratio for a given Ln(III) complex can 
change depending on ligand environment.28 Specifically, increasing the steric strain at the site of water 
coordination has been found to favor adoption of the TSAP geometry in solution, while complexes with 
less bulky substituents tend to favor the SAP geometry.23,28 The increased steric hindrance of the water 
coordination site results in faster bound water-exchange rates due to crowding of the water-coordination 
site, which favors the dissociation of the coordinated water molecule.28 
 
The steric hindrance of a metal complex can be increased in multiple ways. In one study, increasing 
the size of ligand side-chains by one carbon resulted in water exchange rates up to 15 times faster than the 
shorter ligand.29 This same study found that increasing the size of the macrocyclic ring from a 5-membered 
chelate in a DOTA-monoamide ligand to a 7-membered chelate resulted in an acceleration of exchange 
rates by a factor of 69.29 Merbach and coworkers showed that elongating the macrocyclic backbone through 
the addition of an extra carbon was another way to increase the water exchange rate.30 This resulted in a 
water exchange rate that was 100-fold faster.30 The use of bulky phosphonate arms resulted in faster water 
exchange as well due to increased steric hindrance of the molecule.31,32 Lastly, multiple groups showed that 
the ratio of TSAP/SAP geometries increased with an increasing number of alkyl groups between the amide 
group and carboxyl group of the attached sidearm of the ligand.33,34 The general consensus of the mentioned 
studies is that an increase in the steric hindrance of a compound results in an increase in the predominance 
of the TSAP isomer in solution.23,35,36 
 
Project Goal 
The main goal of this project was to develop a library of dual-modality Ln3+ complexes with 
directly coordinated pyridine and quinoline moieties. Pyridine groups have been known to sensitize the 
luminescence of Tb3+ while quinoline groups sensitize the luminescence of Eu3+ through the antenna 
effect.37,38 In this project, we sought to investigate the influence of other non-antenna side-chains on the 
optical and PARACEST MRI properties of the library of complexes. The central hypothesis of this study 
is that the presence of the bulky pyridine and quinoline sidearms would cause a favored adoption of the 
TSAP geometry in solution, and this could potentially result in faster bound water exchange kinetics and a 
reduction of the T2ex effect. These selected antennae were also expected to allow for the sensitization of the 


























3.2 Experimental Methods 
 
Materials and Instrumentation  
 
 All reagents and solvents were purchased from commercial sources and used as received. DI water 
was used in all reactions. Flash Chromatography was carried out using a Buchi Reveleris X2 system. 1H 
and 13C NMR spectra were recorded on a Varian 500 MHz NMR spectrometer. Inductively Coupled Plasma 
was performed using a Perkin Elmer 5300 DV optical emission ICP. High performance liquid 
chromatography (HPLC) was performed using an Agilent 1100 Series HPLC. UV-Vis absorption spectra 
were acquired using a Cary 5000 UV-Vis-NIR spectrophotometer. Luminescence studies were performed 








Scheme 3-1. Synthesis of Ln-MP9b 
 
1-(2-Pyridinylmethyl)-1,4,7,10-tetraazacyclododecane (MP1).  Cyclen (1.999 g, 11.60 mmol) 
and picolyl chloride hydrochloride (0.474 g, 2.89 mmol) were dissolved in CHCl3 (50 mL). K2CO3 (0.478 
g, 3.19 mmol) was added and the reaction mixture was stirred to reflux overnight. The reaction mixture was 
washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer was 
recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH of 
the aqueous layer was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL).  The solution was 
dried with Na2SO4, filtered, and the solvent removed under reduced pressure to give a yellow oil (0.712 g, 
91%). 1H NMR (CDCl3,500 MHz):  2.54-2.57 (m, 4H,  NCH2CH2N), 2.61-2.67 (m, 8H, NCH2CH2N), 







MHz, py-H3), 7.63-7.65 (td, 1H, J = 5 MHz, py-H4), 8.47-8.48 (d, 1H, J = 5 MHz, py-H6). 13C NMR 
(CDCl3,125 MHz):  44.97 46.01, 51.56, 61.01, 122.11, 123.02, 136.66, 148.88, 159.48.  
 
2‐[4,7‐bis(carbamoylmethyl)‐10‐[(pyridin‐2‐yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1-
yl]acetamide  (MP9b). To a solution of 1-(2-Pyridinylmethyl)-1,4,7,10-tetraazacyclododecane (0.362 g, 
1.37 mmol) in acetonitrile (10 mL) and triethylamine (0.766 mL, 5.50 mmol), 2-bromoacetamide (0.587 g, 
4.26 mmol) was added. The mixture was stirred to reflux overnight, and the formation of a white precipitate 
was observed. The precipitate was isolated by vacuum filtration, washed with cold acetonitrile, and left to 
air dry to yield the final product as a white solid (0.328 g, 55%). 1H NMR (D2O, 500 MHz): δ 2.47-2.55 
(m, 16H, NCH2CH2N), 2.9-2.97 (m, 6H, NCH2C=O), 3.53 (s, 2H, NCH2-py), 7.2 (t, 1H, J = 10 MHz, py-
H5), 7.29 (d, 1H, J = 5 MHz, py-H3), 7.67 (td, 1H, J = 10 MHz, py-H4), 8.29 (d, 1H, J = 5 MHz, py-H6). 
13C NMR (D2O, 125 MHz): δ 51.67, 52.36, 57.10, 60.41, 123.12, 124.78, 137.78, 148.14, 177.65. LRMS 
(ESI-MS): m/z  calcd. for C20H36N8O32+, [M+2H]2+, 218.1, found 218.3; calcd. for  C20H35N8O3+, [M+H]+, 













yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}acetate  (MP8).  To a solution of MP1 (0.362 
g, 1.37 mmol) in acetonitrile (25 mL), glycine, N-(2-bromoacetyl)-, 1,1-dimethylethyl ester (1.076 g, 4.26 
mmol) and potassium carbonate (0.7598 g, 5.50 mmol) were added. The mixture was stirred to reflux 
overnight. Potassium carbonate was filtered with a fritted funnel. The solvent was removed under reduced 
pressure, and the crude product was dissolved in dichloromethane (5 mL) and purified by flash 
chromatography (DCM/EtOH 95/5 v/v, Rf = 0.05) to yield an amber solid (0.651 g, 60.96%). 1H NMR 
(CDCl3, 500 MHz): δ 1.36-1.43 (m, 27H, OC(CH3)3), 2.34-2.98 (m, 16H, NCH2CH2N), 3.17-3.38 (m, 6H, 
NCH2C=O), 3.54 (s, 2H, NCH2-py), 3.80-3.90 (m, 6H, NHCH2COO), 7.13 (d, 1H, J = 5 MHz, py-H5), 
7.59 (td, 1H, J = 5 MHz, py-H3), 7.94 (t, 1H, J = 10 MHz, py-H4), 8.37 (d, 1H, J = 5 MHz, py-H6). 13C 
NMR (CDCl3, 125 MHz): δ 28.02, 41.71, 50.42, 57.38, 59.46, 81.54, 123.39, 123.50, 136.81, 150.12, 
158.03, 168.60, 168.86, 171.71, 172.13.  
 
2‐[2‐(4,7‐di{[(carboxylatomethyl)carbamoyl]methyl}‐10‐[(pyridin‐2‐yl)methyl]‐1,4,7,10‐
tetraazacyclododecan‐1‐yl)acetamido]acetate (MP13). MP8 (0.5174 g, 0.665 mmol) was dissolved in 
dichloromethane (4 mL) and added dropwise to a cooled trifluoroacetic acid (6 mL).  The solution was 
stirred at room temperature for 48 h. The solvent was removed under reduced pressure, and the product was 
dissolved in H2O (10 mL). The pH was adjusted to 6 and lyophilized for 72 h to yield a yellow solid (1.332 
g, quantitative). 1H NMR (D2O, 500 MHz): δ 2.98-3.09 (m, 16H, NCH2CH2N), 3.26-3.34 (m, 6H, 
NCH2C=O), 3.54-3.71 (m, 6H, O=CNHCH2), 4.38 (s br, 2H, NCH2-py), 7.38 (t, 1H, J = 5 MHz, py-H5), 
7.46 (d, 1H, J = 10 MHz, py-H3), 7.80 (t, 1H, J = 5 MHz, py-H4), 8.44 (d, 1H, J = 5 MHz, py-H6). 13C 
NMR (D2O, 125 MHz): δ 43.00, 48.87, 55.23, 57.90, 124.76, 128.75, 138.66, 149.66, 162.82, 176.23, 
176.26. LRMS (ESI-MS): m/z  calcd. for C26H42N8O92+, [M+2H]2+, 305.2, found 305.4; calcd. for  









Scheme 3-3. Synthesis of Ln-MP28 
 
1,4‐di‐tert‐butyl 2‐{2‐[4,7‐bis({[1,4‐bis(tert‐butoxy)‐1,4‐dioxobutan‐2‐yl]carbamoyl}methyl)‐
10‐(pyridin‐2‐ylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}butanedioate (MP19).  To a 
solution of MP1 (0.381 g, 1.45 mmol) in acetonitrile (20 mL), 1,4‐di‐tert‐butyl 2‐(2-
chloroacetamido)butanedioate (1.441 g, 4.48 mmol) and potassium carbonate (0.801 g, 5.79 mmol) were 
added. The mixture was stirred to reflux overnight. The solvent was removed under reduced pressure, and 
the crude product was dissolved in dichloromethane (5 mL) and purified by flash chromatography 
(DCM/EtOH 95/5 v/v, Rf = 0.20). Compound MP19 was obtained as a yellow solid (0.917 g, 56.6%). 1H 
NMR (CDCl3, 500 MHz): δ 1.33-1.44 (m, 54H, OC(CH3)3), 2.79-2.92 (m, 16H, NCH2CH2N), 3.08-3.55 
(m, 15H, NCH2CNHCHCH2) 4.65-4.68 (m, 2H, NCH2-py), 7.11 (d, 1H, J = 5 MHz, py-H5), 7.55 (m, 1H, 
py-H3), 7.72 (t, 1H, J = 5 MHz, py-H4), 8.58 (s, 1H, py-H6). 13C NMR (CDCl3, 125 MHz): δ 18.43, 27.89, 










yl]acetamido}butanedioic acid (MP28). MP19 (0.8429 g, 0.753 mmol) was dissolved in dichloromethane 
(4 mL) and added dropwise to cooled trifluoroacetic acid (6 mL).  The solution was stirred at room 
temperature for 48 h. The solvent was removed under reduced pressure, and the crude product was 
redissolved in dichloromethane (5 mL).  The solvent was removed again under reduced pressure and the 
product was dissolved in H2O (10 mL). The pH was adjusted to 6 and lyophilized for 72 h to yield a white 
solid (1.839 g, quantitative). 1H NMR (D2O, 500 MHz): δ 2.34-2.66 (m, 8H, NCH2CH2N), 3.07-3.13 (m, 
8H, NCH2CH2), 3.19 (s br, 2 H, NCH2C=O), 3.28 (s br, 6H, NHCHCH2), 3.34 (s br, 4H, NCH2C=O), 3.98 
(s, 1H, NHCHCH2), 4.26-4.27 (m, 2H, NHCHCH2), 4.47 (s, 2H, NCH2-py), 7.39 (t, 1H, J = 5 MHz, py-
H5), 7.44 (d, 1H, J = 5 MHz, py-H3), 7.81 (t, 1H, J = 10 MHz, py-H4), 8.57 (d, 1H, J = 5 MHz, py-H6). 
13C NMR (D2O, 125 MHz): δ 39.41, 48.41, 50.81, 51.39, 52.99, 53.17, 53.58, 54.24, 54.96, 57.59, 124.52, 
124.78, 138.71, 149.71, 170.41, 178.38, 178.61, 178.66. LRMS (ESI-MS): m/z  calcd. for C32H48N8O152+, 
[M+2H]2+, 392.2, found 392.4; calcd. for C32H47N8O15+, [M+H]+, 783.3, found 783.2; calcd. for 




Scheme 3-4. Synthesis of Ln-MP30 
 
 2‐[(1,4,7,10‐tetraazacyclododecan‐1‐yl)methyl]quinoline (MP27): Cyclen (2.000 g, 11.61 
mmol) and 2-(chloromethyl)quinoline hydrochloride (0.622 g, 2.9 mmol) were dissolved in CHCl3 (50 mL). 
K2CO3 (0.883 g, 6.38 mmol) was added after which the reaction mixture was stirred to reflux overnight.  
The reaction mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The 
aqueous layer was recovered, and the pH adjusted to 8. The layer was then extracted with CHCl3 (3 × 25 







with Na2SO4, filtered, and the solvent removed under reduced pressure to give a yellow/brown oil (0.892 
g, 96%). 1H NMR (CDCl3, 500 MHz): δ 2.57-2.59 (t, 4H, J = 5 MHz, NCH2CH2N), 2.68-2.69 (d, 8H, J = 
5 MHz,  NCH2CH2N), 2.81-2.83 (t, 4H, J = 5 MHz, NCH2CH2N), 3.92 (s, 2H, NCH2-quin), 7.45-7.49 (td, 
1H, J = 5 MHz, quin-H3), 7.58-7.60 (d, 1H, J = 10 MHz, quin-H6), 7.63-7.67 (td, 1H, J = 10 MHz, quin-
H7), 7.74-7.76. (d, 1H, J = 10 MHz, quin-H8), 8.00-8.02 (d, 1H, J = 5 MHz, quin-H5), 8.11-8.13 (d, 1H, J 
= 10 MHz, quin-H4). 13C NMR (CDCl3, 125 MHz): δ 45.13, 46.14, 46.32, 47.11, 51.91, 62.01, 120.87, 
126.06, 127.46, 127.58, 128.88, 129.32, 136.67, 147.51, 160.27 
 
2‐[4,7‐bis(carbamoylmethyl)‐10‐[(quinolin‐2‐yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP30): To a solution of MP27 (0.390 g, 1.24 mmol) in acetonitrile (20 mL) and 
triethylamine (0.6937 mL, 4.98 mmol), 2-bromoacetamide (0.532 g, 3.86 mmol) was added. The mixture 
was stirred to reflux overnight. A white solid formed and the reaction mixture was vacuum filtered. The 
resulting white solid (0.354 g, 59%) was left to air dry. 1H NMR (D2O, 500 MHz): δ 2.28-2.43 (m, 16H, 
NCH2CH2N), 2.71 (s, 4H, NCH2C=O), 2.87-2.91 (m, 2H, NCH2C=O), 3.34 (s, 2H, NCH2-quin), 7.12-7.14 
(d, 1H, J = 10 MHz, quin-H3), 7.35-7.38 (m, 1H, quin-H6), 7.33-7.56 (m, 1H, quin-H7), 7.64-7.66 (d, 1H, 
J = 10 MHz, quin-H8), 7.73-7.75 (d, 1H, J = 10 MHz, quin-H5), 7.96-7.98 (d, 1H, J = 10 MHz, quin-H4). 
13C NMR (D2O, 125 MHz): δ. 51.90, 52.27, 52.50, 56.97, 57.02, 57.15, 61.09, 121.67, 126.85, 126.99, 
127.11, 127.98, 130.35, 137.64, 146.11, 158.66, 177.12, 177.29. LRMS (ESI-MS): m/z calcd. for 
C25H37N8O3+ [M+H]+, 485.3, found 485.4; calcd. for C25H38N8O32+ [M+2H]2+, 243.2, found 243.3; calcd. 









Scheme 3-5. Synthesis of Ln-MP33 
 
 Tert‐butyl 2‐{2‐[4,7‐bis({[2‐(tert‐butoxy)‐2‐oxoethyl]carbamoyl}methyl)‐10‐[(isoquinolin‐3‐
yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}acetate (MP31): To a solution of M27  
(0.416 g, 1.33 mmol) in acetonitrile (20 mL), glycine, N-(2-bromoacetyl)-, 1,1-dimethylethyl ester (0.856 
g, 4.11 mmol) and potassium carbonate (0.735 g, 5.31 mmol) were added. The mixture was stirred to reflux 
overnight. The solvent was removed under reduced pressure, and the crude product was dissolved in 
dichloromethane (5 mL) and purified by flash chromatography (DCM/EtOH 93/7 v/v, Rf = 0.106). 
Compound MP31 was obtained as a golden brown solid (0.488 g, 44.5%). 1H NMR (CDCl3, 500 MHz): δ 
1.19-1.44 (m, 27H, OC(CH3)3), 2.72-3.19 (m, 22H, NCH2CH2NHCH2C=O), 3.82-3.92 (m, 8H, NHCH2-
quin), 7.39-7.41 (d, 1H, J = 10 MHz, quin-H3), 7.50-7.53 (m, 1H, quin-H6),  7.68-7.71 (m, 1H, quin-H7), 
7.77-7.79 (d, 1H, J = 10 MHz, quin-H8), 7.83 (s br, 1H, NCH2C=ONH), 7.99-8.01 (d, 1H, J = 10 MHz, 
quin-H5), 8.07-8.09 (d, 1H, J = 10 MHz, quin-H4), 8.35 (s br, 2H, NCH2C=ONH). 13C NMR (CDCl3, 125 
MHz): δ 25.32, 41.48, 52.61, 52.81, 53.10, 53.23, 58.27, 59.39, 59.69, 62.10, 64.30, 81.58, 81.81, 121.66, 
126.45, 127.16, 127.63, 128.54, 129.87, 136.62, 147.61, 159.19, 168.96, 169.08, 171.50, 171.71 
 
2‐[2‐(4,7‐di{[(carboxymethyl)carbamoyl]methyl}‐10‐[(isoquinolin‐3‐yl)methyl]‐1,4,7,10‐







in dichloromethane (4 mL) and added dropwise to a cooled trifluoroacetic acid (6 mL).  The solution was 
stirred at room temperature for 48 h. The solvent was removed under reduced pressure, and the crude 
product was washed with dichloromethane (2 × 5 mL).  The solvent was removed again under reduced 
pressure and the product was dissolved in H2O (10 mL). The pH was adjusted to 6 and lyophilized for 72 h 
to yield a golden brown solid (1.464 g, quantitative). 1H NMR (D2O, 500 MHz): δ 3.01-3.26 (m br, 16H, 
NCH2CH2N), 3.43-3.75 (m br, 12H, CH2CNHCH2), 4.46 (s, 2H, NCH2-quin), 7.51-7.53 (d, 1H, J = 10 
MHz, quin-H3), 7.56-7.59 (m, 1H, quin-H6), 7.73-7.76 (m, 1H, quin-H7), 7.89-7.90 (d, 1H, J = 5 MHz, 
quin-H8), 8.00-8.02 (d, 1H, J = 10 MHz, quin-H5), 8.30-8.31 (d, 1H, J = 5 MHz, quin-H4). 13C NMR 
(D2O, 125 MHz): δ 30.18, 42.75, 43.23, 51.35, 51.42, 54.87, 58.63, 58.65, 112.80, 115.12, 117.45, 119.77, 
127.80, 128.14, 130.95, 139.02, 146.28, 162.53, 162.81, 163.09, 163.38, 176.04, 176.26. LRMS (ESI-














[(isoquinolin‐3‐yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}butanedioate (MP32): To a 
solution of MP27 (0.492 g, 1.57 mmol) in acetonitrile (20 mL), 1,4‐di‐tert‐butyl 2‐(2-
chloroacetamido)butanedioate (1.566 g, 4.87 mmol) and potassium carbonate (0.870 g, 6.28 mmol) were 
added. The mixture was stirred to reflux overnight. The solvent was removed under reduced pressure, and 
the crude product was dissolved in dichloromethane (5 mL) and purified by flash chromatography 
(DCM/EtOH 95/5 v/v, Rf = 0.209). Compound MP32 was obtained as a golden brown solid (2.309 g, 
56.6%). 1H NMR (CDCl3, 500 MHz): δ 1.37-1.46 (m, 54H,  OC(CH3)3), 2.48-2.82 (m, 28H, NCH2CH2N), 
2.89-3.24 (m, 12H, CH2CNHCHCH2)  3.97-4.12 (m, 2H, NCH2-quin), 4.65 (s br, 3H,  NHCHCH2), 7.47-
7.51 (m, 1H, quin-H3), 7.66-7.69 (m, 1H, quin-H6), 7.74-7.78 (m, 1H, quin-H7), 7.83-7.84 (d br, 1H, J = 
5 MHz, quin-H8), 7.98-8.03 (m, 1H, quin-H5), 8.23-8.27 (m, 1H, quin-H4). 13C NMR (CDCl3, 125 MHz): 
δ 18.42, 27.79, 27.88, 27.90, 27.93, 27.96, 28.00, 28.02, 28.06, 28.08, 28.09, 28.11, 37.28, 37.44, 42.44, 
48.84, 49.33, 52.14, 52.75, 52.88, 53.31, 54.20, 58.36, 59.44, 81.14, 81.90, 81.98, 121.67, 127.42, 127.65, 
128.99, 136.82, 147.56, 169.59, 169.69, 169.75, 170.11, 170.19, 171.02 
  
2‐{2‐[4,7‐bis({[(1,2‐dicarboxyethyl)carbamoyl]methyl})‐10‐[(isoquinolin‐3‐yl)methyl]‐
1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}butanedioic acid (MP34): MP32 (1.042 g, 0.891 mmol) 
was dissolved in dichloromethane (4 mL) and added dropwise to a cooled trifluoroacetic acid (6 mL).  The 
solution was stirred at room temperature for 48 h. The solvent was removed under reduced pressure, and 
the crude product was washed with dichloromethane (2 × 5 mL).  The solvent was removed again under 
reduced pressure and the product was dissolved in H2O (10 mL). The pH was adjusted to 6 and lyophilized 
for 72 h to yield a white solid (2.309 g, quantitative). 1H NMR (D2O, 500 MHz): δ 2.21-2.70 (m, 8H, 
NCH2CH2N), 3.15-3.18 (m, 8H, NCH2CH2N), 3.36-3.67 (m, 12H, CH2CNHCHCH2), 4.04 (s, 1H, 
NHCHCH2), 4.17-4.20 (dd, 2H, J = 5 MHz, NCH2-quin), 4.33-4.36 (dd, 1H, J = 5 MHz, NHCHCH2), 4.46-
4.48 (dd, 1H, J = 10 MHz, NHCHCH2), 7.48-7.50 (d, 1H, J = 10 MHz, quin-H3), 7.57-7.60 (m, 1H, quin-
H6), 7.78-7.81 (m, 1H, quin-H7), 7.89-7.91 (d, 1H, J = 10 MHz, quin-H8), 8.18-8.19 (d, 1H, J = 5 MHz, 
quin-H5), 8.33-8.35 (d, 1H, J = 10 MHz, quin-H4). 13C NMR (CDCl3, 1265MHz): δ 39.29, 39.47, 42.26, 
48.32, 51.10, 52.84, 53.17, 53.24, 53.40, 54.25, 55.17, 58.36, 120.67, 127.73, 127.91, 128.14, 128.25, 
131.07, 139.12, 146.27, 168.78, 177.90, 177.98, 178.27, 178.60, 178.65, 178.76. LRMS (ESI-MS): m/z 











Metal Complexation   
[Eu-MP9b]. MP9b (50 mg, 0.115 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 422 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu3+ 
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z  calcd. for C20H34EuN8O32+, M2+, 293.6, found 293.3. 
 
[Tb-MP9b]. MP9b (101 mg, 0.232 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 1745 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb3+ 
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z  calcd. for C20H34N8O3Tb2+, M2+, 296.6, found 296.3; calcd. for 
C20H34N8O3Tb3+, M3+, 197.7, found 197.9. 
 
[Tm-MP9b].  MP9b (50 mg, 0.115 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 350 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm3+ 
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z  calcd. for C20H34N8O3Tm2+, M2+, 301.6, found 301.3; calcd. for 
C20H34N8O3Tm3+, M3+, 201.1, found 201.2. 
 
[Eu-MP13]. MP13 (106 mg, 0.175 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 645 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu3+ 
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z  calcd. for C26H40EuN8O92+, M2+, 380.6, found 380.3. 
  
[Tb-MP13]. MP13 (106 mg, 0.175 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 1314 L) was added and the solution was stirred 







to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z  calcd. for C26H40N8O9Tb2+, M2+, 383.6, found 383.2; calcd. for 
C26H40N8O9Tb3+, M3+, 256.1, found 255.7. 
 
[Tm-MP13]. MP13 (106 mg, 0.175 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 530 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm3+ 
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z  calcd. for C26H40N8O9Tm2+, M2+, 388.6, found 388.3; calcd. for 
C26H40N8O9Tm3+, M3+, 259.1, found 259.4. 
  
[Eu-MP28]. MP28 (101 mg, 0.131 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 480 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu3+ 
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z  calcd. for C32H45EuN8O152+, [M+2H]2+, 467.1, found 467.3. 
 
[Tb-MP28]. MP28 (101 mg, 0.131 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 990 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb3+ 
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z calcd. for C32H45N8O15Tb2+, M2+, 470.2, found 470.6; calcd. for 
C32H45N8O15Tb3+, M3+, 313.7, found 313.9. 
  
[Tm-MP28]. MP28 (101 mg, 0.131 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 400 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm3+ 
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 







yield a pale yellow solid. LRMS (ESI-MS): m/z calcd. for C32H45N8O15Tm2+, M2+, 475.6, found 475.1; 
calcd. for C32H45N8O15Tm3+, M3+, 317.1, found 317.3. 
  
[Eu-MP30]. MP30 (80 mg, 0.165 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 610 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu3+ 
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z calcd. for C24H36EuN8O32+, M2+, 318.6, found 318.3. 
  
[Tb-MP30]. MP30 (80 mg, 0.165 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 1240 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb3+ 
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z calcd. for C24H36N8O3Tb2+, M2+, 321.6, found 321.4; calcd. for 
C24H36N8O3Tb3+, M3+, 214.4, found 214.7. 
  
[Tm-MP30].  MP30 (50 mg, 0.103 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 315 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm3+ 
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z calcd. for C24H36N8O3Tm3+, M3+, 217.7, found 218.0; calcd. for 
C24H36N8O3Tm2+, M2+, 326.6, found 326.3. 
  
[Eu-MP33]. MP33 (99 mg, 0.151 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 555 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu3+ 
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z calcd. for C30H42EuN8O92+, M2+, 270.4, found 270.7; calcd. for 








[Tb-MP33]. MP33 (99 mg, 0.151 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 1135 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb3+ 
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z calcd. for C30H42N8O9Tb2+, M2+, 408.6, found 408.4; calcd. for 
C30H42N8O9Tb3+, M3+, 272.4, found 272.6. 
  
[Tm-MP33]. MP33 (68 mg, 0.103 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 315 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm3+ 
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a white solid. LRMS (ESI-MS): m/z calcd. for C30H42N8O9Tm3+, M3+, 275.7, found 276.1; calcd. for 
C30H42N8O9Tm2+, M2+, 413.6, found 413.3. 
 
[Eu-MP34]. MP34 (100 mg, 0.120 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 445 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu3+ 
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a golden-brown oil. LRMS (ESI-MS): m/z  calcd. for C36H48EuN8O152+, M2+, 492.6, found 492.3; 
calcd. for C36H48EuN8O153+, M3+, 328.4, found 328.7. 
  
[Tb-MP34]. MP34 (100 mg, 0.120 mmol) was dissolved in H2O (7 mL) and the pH of the solution 
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 910 L) was added and the solution was stirred 
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb3+ 
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a golden-brown oil. LRMS (ESI-MS): m/z  calcd. for C36H48N8O15Tb2+, M2+, 495.6, found 495.2; 
calcd. for C36H48EuN8O15Tb3+, M3+, 330.4, found 330.7. 
  
[Tm-MP34]. MP34 (100 mg, 0.120 mmol) was dissolved in H2O (7 mL) and the pH of the solution 







at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm3+ 
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal 
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to 
yield a golden-brown oil. LRMS (ESI-MS): m/z  calcd. for C36H48N8O15Tm2+, M2+, 500.6, found 500.1; 




 Absorbance spectra were acquired at room temperature using a 1.0 cm quartz cuvette over a 200-
800 nm range with a 5 nm slit. Solutions of each lanthanide complex were prepared at 0.00625 mM using 
0.1 mM HEPES buffer (pH 7.4). 
 
 
Acquisition of Emission Spectra  
Solutions of each lanthanide complex were prepared at 0.1 mM using 0.1 mM HEPES buffer (pH 
7.4). A 450 nm long pass filter was used to eliminate second order peaks by removing longer 
wavelengths. Spectra were recorded at room temperature using a 1.0 cm quartz cell and an excitation 
monochromator slit width of 2 nm. Emission spectra of the Eu3+ and Tb3+complexes were acquired from 
570-750 nm and 450-600 nm, respectively. Individual complexes were excited at the ex listed in Table 3-
1.  
 
Table 3-1. Excitation wavelengths of each compound acquired with an emission monochromator slit 
width of 2 nm. 
Compound Eu-MP9 Eu-MP13 Eu-MP28 Eu-MP30 Eu-MP33 Eu-MP34 
ex (nm) 272 272 274 322 320 320 
              
Compound Tb-MP9 Tb-MP13 Tb-MP28 Tb-MP30 Tb-MP33 Tb-MP34 
ex (nm) 271 272 272 318 319 321 
 
Acquisition of Excitation Spectra  
Solutions of each lanthanide complex were prepared at 0.1 mM using 0.1 mM HEPES buffer (pH 
7.4). A 450 nm long pass filter was used to eliminate second order peaks. Spectra were recorded at room 







spectra of all complexes were acquired from 200-450 nm. Individual spectra were acquired using the em 
indicated in Table 3-2.  
 
Table 3-2. Emission wavelengths of each compound acquired with an excitation monochromator slit 
width of 2 nm. 
Compound Eu-MP9 Eu-MP13 Eu-MP28 Eu-MP30 Eu-MP33 Eu-MP34 
em (nm) 612 613 613 636 633 633 
              
Compound Tb-MP9 Tb-MP13 Tb-MP28 Tb-MP30 Tb-MP33 Tb-MP34 




 Samples were prepared by lyophilizing aliquots of each lanthanide solution in 500 L of 0.1 mM 
HEPES buffer (pH 7.4). One aliquot of each lanthanide solution was then redissolved in D2O and 
lyophilized. These samples were dissolved once more in D2O and lyophilized. Solutions at 0.02 mM 
concentrations were made by dissolving the compounds in HEPES buffer or D2O. Phosphorescent decay 
by delay measurements were acquired using a flash count of 50, sample window of 0.2 ms, 0.05 ms delay 
increment, 5 ms max delay, and an initial delay of 0.05 ms. The intensity versus time data was fit with a 
monoexponential decay to obtain  values. The number of bound water molecules (q) was determined using 
equations 1 and 2 where x represents the number of amide protons in each complex.39 
 
𝑞𝐸𝑢 = 1.2[(𝑘𝐻2𝑂 − 𝑘𝐷2𝑂) − 0.25 − 0.075𝑥]       (1) 
 
𝑞𝑇𝑏 = 5[(𝑘𝐻2𝑂 − 𝑘𝐷2𝑂) − 0.06]     (2) 
   
Quantum Yield () Measurements 
 Absorbance spectra were acquired between 200-800 nm at room temperature, using a 1.0 cm quartz 
cuvette and a 5 nm slit width. Solutions of each lanthanide complex were prepared using 0.1 mM HEPES 
buffer (pH 7.4) such that their absorbance intensities at 315 nm fell between 0.005 and 0.05. Emission 
spectra were acquired upon excitation at 315 nm with collection from 570-750 nm for Eu3+ compounds and 
450-600 nm for Tb3+ compounds. Areas under the emission curves versus absorbance intensities at 315 nm 







manner for reference compounds with known quantum yields. Rhodamine 101 in ethanol ( = 1) and 
fluorescein in 0.1 M NaOH ( = 0.93) were used as reference compounds for Eu3+ and Tb3+ complexes, 
respectively.40,41  Equation 3 was used to determine the quantum yield value of each complex where R 
denotes values corresponding to the reference compound, x corresponds to the unknown sample 
measurements, m represents the slope from the linear fit of the area under the emission curve versus 
absorbance intensity, and n is the refractive index of the solvent used.42 
 
















3.3 Results and Discussion 
 
Absorption Properties of the Tb3+ and Eu3+ Complexes 
Absorption spectra were acquired for each complex to better understand how changes to the antenna, 
ligand side-chains, and metal center affected the photophysical properties of the Tb3+ and Eu3+ complexes. 
It was hypothesized that replacement of the pyridine antenna with a quinoline antenna would alter the 
absorption characteristics of each complex based on previous work with similar chromophores.43,44 The 
quinoline antenna exhibits more conjugation so longer wavelengths of absorption are expected. Normalized 
absorption spectra are shown in Figure 3-6. Absorption in the 250-350 nm range was analyzed as this is the 
region in which  → * and n → * transitions are typically observed for pyridine and quinoline 
compounds.43,45 
 
Figure 3-6. Normalized absorption spectra of 0.0625 mM Tb3+ and Eu3+ complexes in 0.1 M HEPES 
buffer (pH 7.4). (a) and (b) correspond to the Tb3+ and Eu3+ pyridine complexes, respectively; (c) and (d) 
correspond to the Tb3+ and Eu3+ quinoline complexes, respectively. Spectra were acquired at room 
temperature from 200-800 nm. 
 













































































All absorption spectra were found to exhibit similar broad shapes, with the pyridine-containing 
complexes (Figure 3-6a, b) having maximum wavelengths between 271 and 274 nm and those with 
quinoline antenna (Figure 3-6c, d) displaying two peak wavelengths between 300 and 325 nm. These bands 
are attributed to  → * electronic transitions of each antenna.45 For both the pyridine and quinoline 
complexes, maximum wavelengths of absorption were very similar regardless of ligand side-chain identity. 
This indicates that the different ligand side-chains have very little influence on the absorption properties of 
each complex. Additionally, only minor variations in the overall shapes of the absorption spectra were 
observed for the different complexes of the same ligand. This also suggests that metal ion identity has a 
minimal effect on the absorption characteristics of lanthanide complexes of the same ligand.  
 
Evaluation of Excitation Properties 
Excitation spectra were acquired to evaluate the energy needed to excite electrons from the singlet 
ground state to the singlet excited state of the pyridine and quinoline chromophores.46 Following 
intersystem crossing from the singlet excited state to the triplet excited state of the antenna, some of the 
energy absorbed by the antenna is transferred to the Ln3+ excited states.46 Following rapid internal 
conversion to the emitting level of the lanthanide ion, sharp emission lines, characteristic of the metal 









Figure 3-7. Normalized excitation spectra of 0.1 mM complexes in 0.1 mM HEPES buffer (pH 7.4). (a) 
and (b) correspond to the Tb3+ and Eu3+ pyridine complexes, respectively; (c) and (d) correspond to the 
Tb3+ and Eu3+ quinoline complexes, respectively. Spectra were acquired at room temperature from 200-
450 nm with an emission monochromator slit width of 2 nm. em values used to acquire each spectrum 













































































































Table 3-3. Emission and excitation wavelengths of each complex.  
Complex em ex 
Eu-MP9b 612 272 
Eu-MP13 613 272 
Eu-MP28 613 274 
Tb-MP9b 564 271 
Tb-MP13 564 272 
Tb-MP28 564 272 
Eu-MP30 636 322 
Eu-MP33 633 320 
Eu-MP34 633 320 
Tb-MP30 564 318 
Tb-MP33 564 319 
Tb-MP34 564 321 
 
The maximum excitation wavelengths between 271-274 nm for pyridine complexes and 319-322 
nm for quinoline complexes are reflective of  → * electronic transitions.45 This variation in the maximum 
excitation wavelengths between pyridine and quinoline containing complexes is consistent with the 
expectation that the higher conjugation in the quinoline should result in a decrease in energy of the  → * 
electronic transitions. The difference in maximum excitation wavelengths for all complexes with the same 
metal center and antenna was found to be less than 3 nm, thus suggesting that changing the ligand side-
chains had little effect on the excitation properties of each complex. This minimal effect of ligand side-
chain identity was also reflected in the shape similarities of the excitation spectra and consistent with the 
absorption spectroscopy data.  
 
Evaluation of Emission Properties 
The emission spectra of all complexes can be found in Figure 3-8. All spectra display characteristic 
emission profiles of Tb3+ and Eu3+ complexes. For the Tb3+ complexes, sharp emission peaks from 5D4 → 
7FJ, where J = 6, 5, 4, 3, can be observed between 475-630 nm, with the most intense emission peak located 
at 545 nm.48  For the Eu3+ complexes, narrow emission bands from 5D0-7FJ, where J = 0-4, can be observed 








Figure 3-8. Emission spectra of 1 x 10-4 M Tb3+ and Eu3+ complexes in 0.1 M HEPES buffer (pH 7.4). (a) 
and (b) correspond to Tb3+ and Eu3+ pyridine complexes, respectively; (c) and (d) correspond to Tb3+ and 
Eu3+ quinoline complexes. Emission spectra of Eu3+ and Tb3+ were acquired upon excitation at (a) 271 
nm, (b) 272 nm, (c) 319 nm, and (d) 320 nm using 2 nm slit widths. 
 
 
The emission intensities and peak shapes of the terbium complexes can be attributed to the ligand-
field-induced changes in the transition processes.50 For Tb3+ complexes, the peak at approximately 485 nm 
is most susceptible to the ligand environment and does show a change in intensity with varying ligand 
identity.50 Furthermore, the sharp peak at approximately 545 nm is indicative of the ability of each Tb3+ 
complex to emit green light.50 The shape and linewidth of this peak at 545 nm is the same for all complexes, 
indicating that Tb3+ occupies a similar symmetry in all complexes.51 Tb-MP9, Tb-MP13, and Tb-MP28 
have higher emission intensities than Tb-MP30, Tb-MP33, and Tb-MP34, which suggests that the pyridine 
antenna is a more effective sensitizer of Tb3+ luminescence.51,52  
   



























































































For the Eu3+ complexes, the identity of the antenna is clearly affecting the properties of the observed 
emission bands. In particular, the J = 0 and J = 2 bands at 580 nm and 615 nm, respectively, indicate 
structural and photophysical properties of each of the europium complexes. For Eu3+ complexes, the 
hypersensitive J = 2 band at 615 nm is also primarily responsible for the red color observed upon 
excitation.53 There appears to be distinct splitting of this band at 615 nm for all complexes, which can be 
indicative of two components for the 5D0 → 7F2 transition.53 The splitting of the hypersensitive band at 615 
nm is more pronounced for Eu-MP30, Eu-MP33, and Eu-MP34, which corresponds to a higher level of 
asymmetry for those complexes with quinoline antennae than those with pyridine antennae.53 The J = 0 
band at 580 nm is typically weak and forbidden by the Judd-Ofelt theory.53 The sharp peak seen in the 
emission spectra at 580 nm corresponds to a Cnv, Cn, or Cs point group for all Eu3+ complexes.53  
  
 Eu3+ and Tb3+ complexes with MP13, MP28, MP33, and MP34 ligands consistently displayed 
higher emission intensities than those with MP9b and MP30 ligands. This observation can be attributed to 
the presence of twice the amount of amide groups in the MP9b and MP30 ligands. N-H groups cause a 
deactivation of the luminescence of lanthanide complexes through vibrational energy transfer and a larger 
number of these groups will cause a larger loss in emission intensity.39 This quenching effect results in the 
lower emission intensities for the MP9b and MP30 complexes and is observed regardless of the identity of 
the antenna.39  
 
Quantum Yields and q-values 
Quantum yield is a measure of the ratio of emitted photons to absorbed photons.54 It is therefore a 
measurement of the probability that an excited photon will emit light as it relaxes to equilibrium. The overall 
quantum yield also takes into account the energy transfer efficiency from the antenna to the lanthanide ion 
as not all energy absorbed by an antenna will be transferred to the metal center.54 Quantum yields were 
determined using previously published methods.42 The calculated quantum yield values for each complex 
can be found in Table 3-4. 
  
One factor that greatly influences quantum yield values is the energy difference between the triplet 
excited state of the antenna and the emitting level of the lanthanide ion.50 If the energy difference between 
the two levels is too large, energy cannot be transferred from the ligand to the metal center and no emission 
will occur.50 However, if the energy difference is too small, the energy will be transferred back to the 
antenna instead of emitting from the lanthanide ion.50,55 Tb-MP9b, Tb-MP13, and Tb-MP28 exhibited 







that the pyridine antenna has the best photophysical properties for effective sensitization of Tb3+ 
luminescence. This observation is supported by previous studies which have shown that pyridine-based 
antennae enhanced the emission intensities of Tb3+ complexes more than 104-fold.37 Likewise, the quantum 
yields of Eu-MP30, Eu-MP33, and Eu-MP34 are twice as large as those of Eu-MP9b, Eu-MP13, and Eu-
MP28. Similarly, this suggests that the quinoline antenna is a better sensitizer of the luminescence of Eu3+ 
than pyridine moieties. Sensitization of the luminescence of Eu3+ via ligand-to-Eu3+ energy transfer has 
been shown to occur when the ligand triplet state is located below 24000 cm-1 while for Tb3+, the ligand 
triplet state should be higher in energy.50  The emitting level of Eu3+ also lies lower than that of Tb3+, thus, 
the triplet excited state energy level of an efficient sensitizer for Eu3+ does not usually have the same ability 
to sensitize the luminescence of Tb3+.56 
 
Table 3-4.  Lifetime measurement and q values of 0.02 mM complexes in 0.1 mM HEPES buffer (pH 
7.4) and D2O. Calculated quantum yield values of Eu3+ and Tb3+ complexes prepared in 0.1 mM HEPES 
buffer (pH 7.4) using Rhodamine 101 in ethanol ( = 1) and Fluorescein in 0.1 M NaOH ( = 0.93) as a 
reference at 315 nm, respectively.40,41 
Complex  D2O  H2O k D2O k H2O q value 
Quantum 
Yield () 
Eu-MP9b 2.02 0.525 0.494 1.90 0.853a 0.0183 
Eu-MP13 2.17 0.618 0.462 1.62 0.818a 0.0264 
Eu-MP28 2.41 0.600 0.416 1.67 0.930a 0.0229 
Tb-MP9b 4.43 2.38 0.226 0.421 0.676b 0.329 
Tb-MP13 5.98 2.53 0.167 0.396 0.844b 0.355 
Tb-MP28 4.90 2.29 0.204 0.437 0.864b 0.394 
Eu-MP30 1.95 0.546 0.514 1.83 0.743a 0.0436 
Eu-MP33 2.18 0.581 0.459 1.72 0.944a 0.0606 
Eu-MP34 2.27 0.586 0.440 1.71 0.949a 0.0561 
Tb-MP30 1.95 0.546 0.514 1.83 0.743a 0.0128 
Tb-MP33 2.18 0.581 0.459 1.72 0.944a 0.0155 
Tb-MP34 2.27 0.586 0.440 1.71 0.949a 0.0196 
 
aThe number of bound water molecules, q, for Eu3+ complexes  was calculated using the equation  
𝑞 = 1.2[(𝑘𝐻2𝑂 − 𝑘𝐷2𝑂) − 0.25 − 0.075𝑥] where x is the number of amide protons in each complex.    
 
bThe number of bound water molecules, q, for Tb3+ was calculated using the equation                             








 Complexes with MP13, MP28, MP33, and MP34 ligands have higher quantum yields than MP9b 
and MP30 ligands which contain acetamide groups. As previously mentioned, the amide groups on the 
acetamide side-chains quench lanthanide ion emission through vibrational energy transfer.39 As quantum 
yield is related to emission intensity, it is logical that those complexes with more amide groups will have 
both lower emission intensities and quantum yield values. 
  
The long-lived luminescence lifetimes exhibited by Eu3+ and Tb3+ make these lanthanides ideal for 
time-resolved detection as they allow for the acquisition of signal after background autofluorescence has 
subsided.57,58 Using luminescence lifetime values, the number of bound water molecules can be calculated 
through comparison of the luminescence signal decay in both D2O and H2O. Water quenches luminescence 
intensity due to its O-H oscillating groups while the O-D oscillator in D2O has negligible effect.47 This 
allows for the rates of decay in each solvent to be related to the number of lanthanide-bound water molecules 
through the Horrocks equation.39 The measured luminescence lifetime values for each complex and their 
calculated q values can be found in Table 3-4. As expected, the luminescence lifetime of each complex in 
water is shorter than that in D2O. This is due to the quenching effects of O-H oscillators of H2O that are not 
present in D2O. The calculated q values are indicative of one bound water molecule for each complex and 
this is consistent with the expected nine-coordinate geometry of Eu3+ and Tb3+.59 
 
Original measurements of Tb-MP30, Tb-MP33, and Tb-MP34 lifetimes were challenging and 
yielded q values that were either negative or significantly larger than expected for a Tb3+ ion chelated by 
an octadentate ligand. These abnormal values may be due to thermal back transfer from the lanthanide ion 
to the quinoline chromophore. As previously stated, thermal back energy transfer can occur when the ligand 
triplet state energy is too close to that of the metal ion.50,55 The quinoline antennae have been shown through 
quantum yield measurements to be more effective sensitizers of Eu3+ luminescence and may not have a 
high enough triplet state energy level to participate in ligand-to-metal energy transfer with Tb3+. This can 
therefore facilitate easy transfer from the metal ion back to the antenna, which could complicate 
measurements of luminescence lifetimes. Nonetheless, the q-values obtained for the Eu3+ complexes were 
used to extrapolate the number of bound water molecules in the Tb3+ complexes since the europium and 
terbium complexes are isostructural.59 A similar trend can be seen between the q values calculated for the 










In addition to their optical imaging capabilities, paramagnetic lanthanide complexes have the potential 
to produce MR contrast. MR contrast can be produced through the chemical exchange of protons on the 
lanthanide complex with protons of surrounding bulk water by a process known as Chemical Exchange 
Saturation Transfer (CEST).60–62 To evaluate a lanthanide complex’s CEST abilities, CEST spectra are 
acquired by varying irradiation frequency and measuring the change in water proton MR signal intensity.60–
62 These spectra can be used to determine if a lanthanide complex has favorable properties for detection via 
CEST imaging.63 CEST spectra acquired at 298 K and 310 K for the Eu3+ complexes with appended pyridine 
moieties are shown in Figure 3-9. 
 
The large peak at 0 ppm reflects the direct saturation at the bulk water frequency.63,64 The smaller 
peaks shifted to the left of this 0 ppm peak are signal reductions due to the exchange of the Eu3+-bound 
water molecule with bulk water.64 For a PARACEST agent to have adequate CEST properties for imaging, 
it is important for these additional peaks to be shifted as far away as possible from the saturated water peak. 
The exchange rate (kex) must also be lower than the chemical shift difference () between the two 
exchanging pools of water or protons.65 Paramagnetic chelates are of particular interest for CEST imaging 
as  is much larger in these chelates than in diamagnetic compounds.65 A larger  not only ensures that 
selectively saturating bound water protons does not result in the direct saturation of bulk water protons, but 
also allows the use of PARACEST agents with faster exchange rates.66,67   
 
In the CEST spectra acquired at 298 K, all complexes show two peaks shifted from the saturated water 
peak with a more prominent signal at approximately 40 ppm and a small shoulder shifted 10-15 ppm further. 
Exact values of these peaks for each complex can be found in Table 3-5. These shifted peaks correspond to 
exchange between bulk water protons and Eu3+-bound water molecules and is consistent with the fact that 
each complex has one bound water molecule regardless of ligand identity. In previous studies of Eu3+-
DOTA-tetraamide complexes, peaks located at approximately 50 ppm have been attributed to exchange 
between bound and bulk water molecules.68 Similar signals at ~50 ppm have been observed for Eu-DOTA 
complexes with appended glycinamide groups.68,69  The presence of two peaks with similar chemical shifts 
may be indicative of two different SAP isomers in solution with the peak at approximately 40 ppm 








Figure 3-9. CEST spectra of Eu3+ (10 mM) acquired at 9.4 T, 298 K (Figure a) and 310 K (Figure b). 
Spectra were acquired at pH = 7, B1 = 18.8 μT, and irradiation time = 5 s.  
 
 
 The broad nature of the Eu-MP9b peak also indicates that water exchange in the complex is faster 
compared to Eu-MP13 and Eu-MP28. Carboxylate groups have been shown to decrease water exchange 
rates by establishing hydrogen bond networks that stabilize the bound water molecule and therefore hinder 
access to other water molecules.32,70 The presence of carboxylate groups in Eu-MP13 and Eu-MP28 could 











































also displayed the largest CEST intensity and this can be attributed to the fact that it has more exchangeable 
amide protons in comparison to the other complexes. The presence of more amide protons has been shown 
to result in a greater decrease in bulk water signal.62 Additionally, the absence of carboxylate groups in this 
complex allows for easier access of the lanthanide ion center to exchanging water molecules and therefore 
results in more saturation transfer to the bulk water.  
  
Table 3-5. CEST exchange peaks for the Eu3+-pyridine complexes.  
 










Eu-MP9b 42 53 38 - 
Eu-MP13 42 54 39 - 
Eu-MP28 43 54 40 50 
 
Increasing the temperature to 310 K resulted in the elimination of the secondary peaks for Eu-MP9b 
and Eu-MP13. The main peaks at approximately 40 ppm broadened with increasing temperature for Eu-
MP9 and Eu-MP13. At higher temperatures, CEST peaks of various Eu3+ complexes have been found to 
broaden and shift upfield toward the bulk water resonance.27 The broadening of the peaks is indicative of 
an increasing exchange rate which occurs as temperature increases according to the Arrhenius equation.64,62 
The secondary peak of Eu-MP28 is still present, though with a lower intensity. This suggests that water 
exchange in this complex is still slow enough to produce an observable CEST signal. Furthermore, the 
intensity of the main peak at 40 ppm increased at higher temperature, which is indicative of Eu-MP28 
having more ideal CEST capabilities at 310 K. However, once the optimum temperature has been exceeded, 
the CEST peak is expected to become even broader, shift closer toward the bulk water peak, and 




 A library of Eu3+ and Tb3+ complexes was successfully synthesized and the effect of ligand side-
chains on the optical and magnetic resonance imaging properties of these complexes was evaluated. Ligand 
identity was found to have little effect on the absorption and excitation properties of the complexes but 
significantly impacted the emission intensities and quantum yield values of the complexes in this study. 
Complexes of the MP9b and MP30 ligands consistently displayed lower quantum yield values and this was 
attributed to the quenching of the emission intensity brought about by the additional amide groups in their 







which allowed the investigation of their PARACEST MRI properties. Eu-MP9b exhibited the broadest 
CEST peaks and largest CEST signals. These characteristics were attributed to the faster water exchange 
kinetics of this complex. Eu-MP13 and Eu-MP28 displayed sharper and less intense peaks at both 298 K 
and 310 K due to hydrogen-bond networks formed by the carboxylate groups in the ligand side-chains. The 
presence of these networks caused a deceleration of the water exchange rates in these complexes and a 
resultant decrease in CEST effect. The CEST signal of Eu-MP28 was found to increase at higher 




3.5 Future Work  
 
 The initial goal of this project was to determine if the incorporation of a bulky pyridine or quinoline 
moiety would favor the adoption of the TSAP geometry in solution. To evaluate the ratio of TSAP and SAP 
isomers in solution, 1H NMR is typically used to distinguish each isomer by its unique chemical shift.24,71 
This particular goal was not met due to instrumentation limitations. We hope to be able to perform this 
experiment in the near future in order to test the above hypothesis. Since faster proton exchange rates 
associated with the TSAP isomer has been shown to overcome the loss of CEST signal through the T2ex 
mechanism, we believe that designing agents that preferentially adopt the TSAP geometry, and produce 
CEST signal through amide proton exchange, would result in PARACEST agents that can be utilized for 
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Appendix A. Supporting Data 
 
A.1 NMR Spectra 
 
 








































































































































































































































































































































































































































A.2 HPLC Methods and Chromatograms 
 
HPLC Methods. HPLC analyses were performed with an Agilent Technologies 1100 system. 
  
Method A. Solvent A = 0.1% TFA in Water, Solvent B = 0.1% TFA in Acetonitrile, Flow Rate = 0.2 
mL/min, Column = Kinetex 2.6µm XB-C18 100 Å, HPLC Column 150 x 4.6 mm. 0-1 min (5% B), 1-11 
min (5% B to 8% B) 
  
Method B. Solvent A = 0.1% TFA in Water, Solvent B = 0.1% TFA in Acetonitrile, Flow Rate = 0.5 
mL/min, Column = Phenomenex Luna® 5 µm C18(2) 100 Å, LC Column 150 x 4.6 mm. 0-2 min (5% B), 
2-10 min (5% B to 30% B), 10-11 min (30% B) 
 
Method C. Solvent A = 0.1% TFA in Water, Solvent B = 0.1% TFA in Acetonitrile, Flow Rate = 0.5 
mL/min, Column = Phenomenex Luna® 5 µm C18(2) 100 Å, LC Column 150 x 4.6 mm. 0-2 min (5% B), 
2-10 min (5% B to 20% B), 10-11 min (30% B) 
 
 
Figure A-66. HPLC chromatogram of MP30 acquired with Method A at 254 nm.  
 

















Figure A-67. HPLC chromatogram of MP42 acquired with Method A at 254 nm.  
 
 
Figure A-68. HPLC chromatogram of MP43 acquired with Method A at 254 nm. 
 
 


























Figure A-69. HPLC chromatogram of MP44 acquired with Method A at 254 nm.  
 
 
Figure A-70. HPLC chromatogram of MP45 acquired with Method A at 254 nm.  
 































Figure A-72. HPLC chromatogram of MP47 acquired with Method A at 254 nm.  
 





















































Figure A-75. HPLC chromatogram of Eu-MP42 acquired with Method B at 254 nm.  
 
 































Figure A-77. HPLC chromatogram of Eu-MP44 acquired with Method B at 254 nm.  
 


























Figure A-78. HPLC chromatogram of Eu-MP45 acquired with Method B at 254 nm.  
 
 
Figure A-79. HPLC chromatogram of Eu-MP46 acquired with Method B at 254 nm.  
 
 



























Figure A-80. HPLC chromatogram of Eu-MP47 acquired with Method B at 254 nm.  
 
 
Figure A-81. HPLC chromatogram of Eu-MP48 acquired with Method B at 254 nm.  
 
 

































Figure A-83. HPLC chromatogram of MP13 acquired with Method A at 254 nm.  
 
























































































































































































































































Figure A-97. HPLC chromatogram of Tb-MP34 acquired with Method B at 254 nm. 
 





































Figure A-99. HPLC chromatogram of Tm-MP13 acquired with Method B at 254 nm. 
 

































Figure A-101. HPLC chromatogram of Tm-MP30 acquired with Method B at 254 nm. 
 






























Figure A-103. HPLC chromatogram of Tm-MP34 acquired with Method B at 254 nm. 
 
  
























A.3 Phosphorescence Spectra 
 
 
Figure A-104. Phosphorescence emission spectrum of Gd-MP30 (1 mM) in 10 mM HEPES buffer (pH 7) 
acquired with ex = 309 nm. 
 
 
Figure A-105. Phosphorescence emission spectrum of Gd-MP42 (1 mM) in 10 mM HEPES buffer (pH 7) 
acquired with ex = 322 nm. 
 

































































Figure A-106. Phosphorescence emission spectrum of Gd-MP43 (1 mM) in 10 mM HEPES buffer (pH 7) 
acquired with ex = 326 nm. 
 
 
Figure A-107. Phosphorescence emission spectrum of Gd-MP44 (1 mM) in 10 mM HEPES buffer (pH 7) 
acquired with ex = 350 nm. 
 

































































Figure A-108. Phosphorescence emission spectrum of Gd-MP45 (1 mM) in 10 mM HEPES buffer (pH 7) 
acquired with ex = 320 nm. 
 
 
Figure A-109. Phosphorescence emission spectrum of Gd-MP46 (1 mM) in 10 mM HEPES buffer (pH 7) 
acquired with ex = 324 nm. 
 
 

































































Figure A-110. Phosphorescence emission spectrum of Gd-MP47 (1 mM) in 10 mM HEPES buffer (pH 7) 
acquired with ex = 338 nm. 
 
 
Figure A-111. Phosphorescence emission spectrum of Gd-MP48 (1 mM) in 10 mM HEPES buffer (pH 7) 
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